[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_1747d45a-3bcf-4ece-805f-7d284fd0374a":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:1747d45a-3bcf-4ece-805f-7d284fd0374a,\"}":99},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":29,"indexDatabases":52,"url":91,"thumbnailPath":18,"statistic":92,"gsStatistic":18,"type":98,"analyzePriority":18},"1747d45a-3bcf-4ece-805f-7d284fd0374a","2024-04-11T06:19:27.856+00:00","2025-11-21T09:48:13.647+00:00",[],"Cost-Effectiveness-and-Resource-Allocation",{"issn":12,"title":14},{"VOID":13},"1478-7547",{"EN":15},"Cost Effectiveness and Resource Allocation","PUBLISHER","PENDING",null,0,[21],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"8a494f62-57a5-4668-b75a-4307e7d55da0","2023-05-29T10:24:05.334+00:00","2023-11-21T08:04:43.825+00:00",[],{"EN":27},"Health Policy",{},[30,42],{"id":31,"createTime":32,"updateTime":33,"relativeEntities":34,"slug":35,"properties":36,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":40,"url":18,"parentIds":41,"statistic":18},"c5894808-4e99-4047-bbce-594f58821845","2023-05-29T10:24:08.212+00:00","2025-11-21T10:07:05.787+00:00",[],"BioMed-Central-Ltd-",{"title":37},{"EN":38},"BioMed Central Ltd.","AFFILIATION",10,[],{"id":43,"createTime":44,"updateTime":45,"relativeEntities":46,"slug":47,"properties":48,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":50,"url":18,"parentIds":51,"statistic":18},"67883518-0c98-470e-b6b0-160ab49bb03d","2023-05-29T12:06:59.969+00:00","2024-02-19T18:45:45.100+00:00",[],"BMC",{"title":49},{"EN":47},9,[],[53,72],{"id":54,"indexDatabase":55,"url":67,"indexYears":68,"academicFieldIds":69,"indexDatabaseRanking":71},"9be5c158-159b-4050-a1df-b882ad18fe20",{"id":56,"createTime":57,"updateTime":58,"relativeEntities":59,"label":60,"description":62,"key":64,"publicationTags":65,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":61,"VI":61},"Scopus - Elsevier",{"EN":61,"VI":63},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[66],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F12788","2003-2025",[70],"c988b05f-b47d-441e-b68f-0d781b8bc15f","SCOPUS__Q1",{"id":73,"indexDatabase":74,"url":88,"indexYears":18,"academicFieldIds":89,"indexDatabaseRanking":18},"8d67c382-b66b-410c-b56d-c45c85d08678",{"id":75,"createTime":76,"updateTime":77,"relativeEntities":78,"label":79,"description":81,"key":84,"publicationTags":85,"standard":18},"a8273be3-1221-4f26-949d-71dc71ff1fc3","2023-05-22T09:59:54.622+00:00","2025-11-21T10:07:52.181+00:00",[],{"EN":80,"VI":80},"ISI-SSCI -  Social Sciences Citation Index",{"VI":82,"EN":83},"Cơ sở dữ liệu SSCI","SSCI database","ssci",[86,87],"SSCI","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1478-7547",[90],"4196d69a-5d02-4658-a11d-a815b2e0b9bd","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F12962",{"impactFactor":19,"impactFactorByYear":93,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":95,"totalCitation":19,"totalCitationByYear":96,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":97,"hindexLast5Year":19,"hindex":19},{},1,{"2021":94},{},{},"JOURNAL",{"meta":100,"data":102},{"total":101},"479",[103,190,340,486,731,886,1072,1150,1308,1461],{"id":104,"createTime":105,"updateTime":106,"relativeEntities":107,"slug":108,"properties":109,"entityType":118,"verifyStatus":119,"verifyTime":106,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":121,"fullTextUrl":18,"authors":122,"publicationType":153,"publisherRelationship":154,"citationCount":18,"citationInfo":18,"publishDate":187,"publishYear":188,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"379ff667-0c6a-4c8d-9fc2-5b09b6a1e6b3","2024-01-10T20:49:52.229+00:00","2025-01-21T23:58:24.672+00:00",[],"Medical-advice-seeking-behaviors-based-on-transaction-cost-theory",{"references":110,"abstract":112,"title":114,"doi":116},{"VOID":111},"Coase RH. The nature of the firm. Economica. 1937;4(16):386–405.\nCreswell JW, Plano Clark VL, Gutmann ML, Hanson WE. Advanced mixed methods research designs. In: Tashakkori A, Teddlie C, editors. Handbook on mixed methods in the behavioral and social sciences. Thousand Oaks: Sage Publications; 2003. p. 209–40.\nDahlman CJ. The problem of externality. J Law Econ. 1979;22(1):141–62.\nDavid RJ, Han SK. A systematic assessment of the empirical support for transaction cost economics. Strat Manag J. 2004;25(1):39–58.\nFan SP. Political and economic factors in the foreign trade system of mainland China: an analysis applying transaction cost theory. 1998.\nHuang PL. Establishment of an integrated intelligent Health Care Network: a case study of the medical steward project in Zhongli. Taiwan: National Central University; 2016.\nLiao CH. Listed companies issue securities and trade on-line directly in transaction cost theory. Taoyuan: National Central University; 2009.\nLiu FW, Li L, Xue YK. Trust, transaction cost and mode of trade credit. Econ Res J. 2009;8:60–72.\nSolomon MR. Consumer behavior: buying, having, and being, vol. 10. Engelwood Cliffs: Prentice Hall; 2014.\nWilliamson OE. The economic intstitutions of capitalism. New York: Simon and Schuster; 1985.\nYin RK. Applications of case study research. Thousand Oaks: Sage Publications; 2011.",{"EN":113},"Given the global trend of aging societies, medical expenditure has hit record highs in many countries. Because medical advice-seeking behaviors can affect the health of whole societies, how members of a society make medical-related decisions with limited available resources is worthy of investigation. Although transaction cost theory has been extensively applied in commercial research, it is yet to be applied in studies on medical advice-seeking behaviors. This study conducted in-depth interviews with 15 participants and verified that transaction cost theory is applicable for analyzing people’s medical advice-seeking behaviors. This study verified that transaction cost theory influenced the participants’ choices of physicians and treatment methods, which implies that improved transparency of medical information could considerably reduce transaction costs in relation to medical behaviors and enhance people’s well-being.",{"EN":115},"Medical advice-seeking behaviors based on transaction cost theory",{"VOID":117},"10.1186\u002Fs12962-018-0167-y","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-018-0167-y",[123,141],{"id":124,"sortIndex":19,"researcher":18,"roles":125,"affiliations":127,"properties":138},"7a2e9367-a894-42b4-9cd6-6369eca02226",[126],"AUTHOR",[128],{"id":18,"sortIndex":19,"affiliation":129,"properties":18},{"id":130,"createTime":131,"updateTime":132,"relativeEntities":133,"slug":134,"properties":135,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"178f7cb4-a5b9-47d7-96f7-bf05998a4e7d","2023-12-23T12:58:38.553+00:00","2025-02-09T16:33:07.455+00:00",[],"Taipei-Taiwan",{"title":136},{"VI":137},"Taipei, Taiwan",{"title":139},{"VI":140},"Shih Han Lin",{"id":142,"sortIndex":94,"researcher":18,"roles":143,"affiliations":144,"properties":150},"12ee818a-e9dc-4a83-bfe0-b4e4ad5df569",[126],[145],{"id":18,"sortIndex":19,"affiliation":146,"properties":18},{"id":130,"createTime":131,"updateTime":132,"relativeEntities":147,"slug":134,"properties":148,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":149},{"VI":137},{"title":151},{"VI":152},"Tom M. Y. Lin","ARTICLE",{"url":121,"publisher":155,"properties":182},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":156,"slug":10,"properties":157,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":160,"manageAffiliations":161,"indexDatabases":162,"url":91,"thumbnailPath":18,"statistic":177,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":158,"title":159},{"VOID":13},{"EN":15},[],[],[163,170],{"id":54,"indexDatabase":164,"url":67,"indexYears":68,"academicFieldIds":169,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":165,"label":166,"description":167,"key":64,"publicationTags":168,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":171,"url":88,"indexYears":18,"academicFieldIds":176,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":172,"label":173,"description":174,"key":84,"publicationTags":175,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":178,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":179,"totalCitation":19,"totalCitationByYear":180,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":181,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":183,"pages":185},{"VOID":184},"16",{"VOID":186},"1-6","2018-12-14",2018,false,{"id":191,"createTime":192,"updateTime":193,"relativeEntities":194,"slug":195,"properties":196,"entityType":118,"verifyStatus":119,"verifyTime":193,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":205,"fullTextUrl":18,"authors":206,"publicationType":153,"publisherRelationship":305,"citationCount":18,"citationInfo":18,"publishDate":338,"publishYear":339,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"3d5fea69-dcf2-4ecb-8540-71adb64faf31","2023-12-25T20:22:15.093+00:00","2024-12-08T23:46:05.619+00:00",[],"Developing-and-validating-a-multi-criteria-decision-analytic-tool-to-assess-the-value-of-cancer-clinical-trials-evaluating-cancer-clinical-trial-value",{"references":197,"abstract":199,"title":201,"doi":203},{"VOID":198},"Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7).\nDiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.\nSullivan F. Australia : Preferred Destination for Early Phase Clinical Trials. 2016.\nHeath A, Myriam Hunink MG, Krijkamp E, Pechlivanoglou P. Prioritisation and design of clinical trials. Eur J Epidemiol. 2021;36(11):1111–21.\nSchnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–33.\nCherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–66.\ndel Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017;18(7).\nDavis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer Drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017.\nVivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new Drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28(5):1111–6.\nHiggins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online). 2011.\nJadad A, Moore A, Carrol D, Jenkinson C, Reynolds J, Gavghan D et al. Assessing the quality of reports of Randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;1–12.\nCho MK, Bero L. a. instruments for assessing the quality of Drug studies published in the Medical Literature. JAMA. 2010;14–7.\nNuromohamed M, Rosendaal F, Buller H, Dekker E, Hommes D, Vandenbroucke J, et al. Low-molecular weight heparin versus standard heparin in general and other orthopaedic Surgery: a meta-analysis. The Lancet. 1992;10(3):131–4.\nVerhagen A, de Vet H, de Bie R, Kessels A, Boers M, Bouter L, et al. The Delphi list: a Criteria List for Quality Assessment of Randomized clinical trials for conducting systematic reviews developed by Delphi Consensus. J Clin Epidemiol. 1998;51(12):1235–41.\nThokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z et al. Multiple criteria decision analysis for health care decision making - an introduction: Report 1 of the ISPOR MCDA Emerging Good practices Task Force. Value in Health. 2016.\nHummel JM, Bridges JFP, IJzerman MJ. Group decision making with the analytic hierarchy process in benefit-risk assessment: a tutorial. Patient. 2014.\nOliveira MD, Mataloto I, Kanavos P. Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. Eur J Health Econ. 2019.\nAdunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. Health Expectations. 2015.\nMarsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, et al. Multiple Criteria Decision Analysis for Health Care decision making - emerging Good practices: Report 2 of the ISPOR MCDA Emerging Good practices Task Force. Value in Health. 2016;19(2):125–37.\nChapple CR, Mironska E, Wagg A, Milsom I, Diaz DC, Koelbl H, et al. Multicriteria decision analysis Applied to the clinical use of Pharmacotherapy for overactive bladder Symptom Complex. Eur Urol Focus. 2020;6(3):522–30.\nAhuja S, Phillips L, Smartt C, Khalid S, Coldham T, Fischer L et al. What interventions should we implement in England’s mental health services? The mental health implementation network (MHIN) mixed-methods approach to rapid prioritisation. Front Health Serv. 2023;3.\nGuthrie S, Krapels J, Lichten C, Wooding S. 100 Metrics to assess and communicate the Value of Biomedical Research: an ideas Book. RAND Corporation; 2016.\nDeshpande A, Guthrie S, Cox C, Bertscher A. Development of metrics to measure the impact of Tommy’s work. RAND Corporation; 2018.\nPoll Everywhere. https:\u002F\u002Fwww.polleverywhere.com\u002F. 2019. Poll Everywhere.\nQualtrics. Qualtrics. Provo. Utah, USA: Qualtrics; 2020.\nBarron FH, Barrett BE. Decision quality using ranked attribute weights. Manage Sci. 1996;42(11):1515–23.\nR Core Team. R: a language and environment for statistical computing. Vienna. Austria: R Foundation for Statistical Computing; 2020.\nGillett P, Mahar RK, Tran NR, Rosenthal M, IJzerman M. An R Shiny app retrospectively valuing clinical trials using MCDA [Internet]. 2020 [cited 2022 Jun 22]. Available from: https:\u002F\u002Fcancerhealthservices.shinyapps.io\u002FValuingClinicalTrials\u002F?_ga=2.1086130223167595.1595799553-25929989.1593641240.\nHammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in patients with locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib. JAMA. 2016;315(17):1844.\nRombouts SJ, Mungroop TH, Heilmann MN, van Laarhoven HW, Busch OR, Molenaar IQ, et al. FOLFIRINOX in locally Advanced and metastatic Pancreatic Cancer: a single Centre Cohort Study. J Cancer. 2016;7(13):1861–6.\nYang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive Surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric Cancer: final results of a phase III Randomized Clinical Trial. Ann Surg Oncol. 2011;18(6):1575–81.\nSledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on overall survival in hormone Receptor–Positive, ERBB2-Negative Breast Cancer that progressed on endocrine Therapy—MONARCH 2. JAMA Oncol. 2020;6(1):116.\nShroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers. JAMA Oncol. 2019;5(6):824.\nBennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ. Development and evaluation of an Approach to using value of information analyses for real-time prioritization decisions within SWOG, a large Cancer clinical trials Cooperative Group. Med Decis Making. 2016;36(5):641–51.\nMarsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the Value of Healthcare Interventions Using Multi-criteria Decision Analysis: a review of the literature. PharmacoEconomics. 2014;32(4):345–65.\nIdentifying. and selecting a clinical trial for your practice. J Oncol Pract. 2008;4(1):27–8.",{"EN":200},"Demonstrating safety and efficacy of new medical treatments requires clinical trials but clinical trials are costly and may not provide value proportionate to their costs. As most health systems have limited resources, it is therefore important to identify the trials with the highest value. Tools exist to assess elements of a clinical trial such as statistical validity but are not wholistic in their valuation of a clinical trial. This study aims to develop a measure of clinical trials value and provide an online tool for clinical trial prioritisation. A search of the academic and grey literature and stakeholder consultation was undertaken to identify a set of criteria to aid clinical trial valuation using multi-criteria decision analysis. Swing weighting and ranking exercises were used to calculate appropriate weights of each of the included criteria and to estimate the partial-value function for each underlying metric. The set of criteria and their respective weights were applied to the results of six different clinical trials to calculate their value. Seven criteria were identified: ‘unmet need’, ‘size of target population’, ‘eligible participants can access the trial’, ‘patient outcomes’, ‘total trial cost’, ‘academic impact’ and ‘use of trial results’. The survey had 80 complete sets of responses (51% response rate). A trial designed to address an ‘Unmet Need’ was most commonly ranked as the most important with a weight of 24.4%, followed by trials demonstrating improved ‘Patient Outcomes’ with a weight of 21.2%. The value calculated for each trial allowed for their clear delineation and thus a final value ranking for each of the six trials. We confirmed that the use of the decision tool for valuing clinical trials is feasible and that the results are face valid based on the evaluation of six trials. A proof-of-concept applying this tool to a larger set of trials with an external validation is currently underway.",{"EN":202},"Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value",{"VOID":204},"10.1186\u002Fs12962-023-00496-y","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-023-00496-y",[207,233,255,268,293],{"id":208,"sortIndex":209,"researcher":18,"roles":210,"affiliations":211,"properties":230},"f5befd3f-8218-4f05-8fff-b48149f69acf",4,[126],[212,220],{"id":18,"sortIndex":19,"affiliation":213,"properties":18},{"id":214,"createTime":215,"updateTime":215,"relativeEntities":216,"slug":18,"properties":217,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b8c88133-8b0e-4e98-9568-57d8e6bacf7c","2023-12-25T20:22:15.214+00:00",[],{"title":218},{"VI":219},"Cancer Health Services Research Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia",{"id":221,"sortIndex":94,"affiliation":222,"properties":229},"bf55035e-42b0-41f8-85f4-98a3586f1323",{"id":223,"createTime":224,"updateTime":224,"relativeEntities":225,"slug":18,"properties":226,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"722a33a4-d427-4b4d-94b8-c7be36c68d7a","2024-01-11T18:07:55.276+00:00",[],{"title":227},{"VI":228},"Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Australia",{},{"title":231},{"VI":232},"Maarten IJzerman",{"id":234,"sortIndex":94,"researcher":18,"roles":235,"affiliations":236,"properties":252},"ebd612b4-830c-4b4a-a2a1-28477137ac7b",[126],[237,242],{"id":18,"sortIndex":19,"affiliation":238,"properties":18},{"id":214,"createTime":215,"updateTime":215,"relativeEntities":239,"slug":18,"properties":240,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":241},{"VI":219},{"id":243,"sortIndex":94,"affiliation":244,"properties":251},"08525fd3-24bc-4b88-9f91-9dfd93efba65",{"id":245,"createTime":246,"updateTime":246,"relativeEntities":247,"slug":18,"properties":248,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3c4ca92e-a755-4961-a72d-e4a1d24595c0","2023-12-25T20:22:15.130+00:00",[],{"title":249},{"VI":250},"Biostatistics Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia",{},{"title":253},{"VI":254},"Robert K Mahar",{"id":256,"sortIndex":257,"researcher":18,"roles":258,"affiliations":259,"properties":265},"58e54fee-b84f-48ba-be0d-46a7f3100c6f",2,[126],[260],{"id":18,"sortIndex":19,"affiliation":261,"properties":18},{"id":214,"createTime":215,"updateTime":215,"relativeEntities":262,"slug":18,"properties":263,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":264},{"VI":219},{"title":266},{"VI":267},"Nancy R Tran",{"id":269,"sortIndex":270,"researcher":18,"roles":271,"affiliations":272,"properties":290},"6a5c2d18-6660-4831-836b-56a4f62ec204",3,[126],[273,278],{"id":18,"sortIndex":19,"affiliation":274,"properties":18},{"id":223,"createTime":224,"updateTime":224,"relativeEntities":275,"slug":18,"properties":276,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":277},{"VI":228},{"id":279,"sortIndex":94,"affiliation":280,"properties":289},"569be012-0994-460f-bc83-148f4f3ee3f8",{"id":281,"createTime":282,"updateTime":283,"relativeEntities":284,"slug":285,"properties":286,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"05486534-c003-45a5-9723-68787e9303ba","2023-12-25T20:22:15.322+00:00","2025-06-11T18:28:14.422+00:00",[],"Department-of-Medical-Oncology-The-Royal-Melbourne-Hospital-Melbourne-Australia",{"title":287},{"VI":288},"Department of Medical Oncology, The Royal Melbourne Hospital, Melbourne, Australia",{},{"title":291},{"VI":292},"Mark Rosenthal",{"id":294,"sortIndex":19,"researcher":18,"roles":295,"affiliations":296,"properties":302},"3ee5290c-839b-42aa-82bf-8cefec19b713",[126],[297],{"id":18,"sortIndex":19,"affiliation":298,"properties":18},{"id":214,"createTime":215,"updateTime":215,"relativeEntities":299,"slug":18,"properties":300,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":301},{"VI":219},{"title":303},{"VI":304},"Piers Gillett",{"url":205,"publisher":306,"properties":333},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":307,"slug":10,"properties":308,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":311,"manageAffiliations":312,"indexDatabases":313,"url":91,"thumbnailPath":18,"statistic":328,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":309,"title":310},{"VOID":13},{"EN":15},[],[],[314,321],{"id":54,"indexDatabase":315,"url":67,"indexYears":68,"academicFieldIds":320,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":316,"label":317,"description":318,"key":64,"publicationTags":319,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":322,"url":88,"indexYears":18,"academicFieldIds":327,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":323,"label":324,"description":325,"key":84,"publicationTags":326,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":329,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":330,"totalCitation":19,"totalCitationByYear":331,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":332,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":334,"pages":336},{"VOID":335},"21",{"VOID":337},"1-9","2023-11-14",2023,{"id":341,"createTime":342,"updateTime":343,"relativeEntities":344,"slug":345,"properties":346,"entityType":118,"verifyStatus":119,"verifyTime":343,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":355,"fullTextUrl":18,"authors":356,"publicationType":153,"publisherRelationship":452,"citationCount":18,"citationInfo":18,"publishDate":484,"publishYear":485,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"beffbf13-654f-4788-8a04-3c40df504387","2024-01-21T02:35:08.147+00:00","2024-12-16T23:43:57.766+00:00",[],"Cost-effectiveness-of-pharmacological-and-psychosocial-interventions-for-schizophrenia",{"references":347,"abstract":349,"title":351,"doi":353},{"VOID":348},"Barbato A: Schizophrenia and public health. Geneva: World Health Organization; 1998.\nBundhamcharoen K, Teerawatananon Y, Vos T, Begg S: Burden of disease and injuries in Thailand: priority setting for policy. Nonthaburi: Ministry of Public Health; 2002.\nKnapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull 2004, 30: 279–293.\nLang H-C, Su T-P: The Cost of Schizophrenia Treatment in Taiwan. Psychiatr Serv 2004, 55: 928–930. 10.1176\u002Fappi.ps.55.8.928\nChang SM, Cho S-J, Jeon HJ, Hahm B-J, Lee HJ, Park J-I, Cho MJ: Economic burden of schizophrenia in South Korea. Korean Med Sci 2008, 23: 167–175. 10.3346\u002Fjkms.2008.23.2.167\nKessler RC, Frank RG: The impact of psychiatric disorder on work loss days. Psychol Med 1997, 27: 861–873. 10.1017\u002FS0033291797004807\nLang HC, Su TP: The cost of schizophrenia treatment in Taiwan. Psychiatr Serv 2004, 55: 928–930. 10.1176\u002Fappi.ps.55.8.928\nLee IH, Chen PS, Yang YK, Liao YC, Lee YD, Yeh TL, Yeh LL, Cheng SH, Chu CL: The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res 2008, 158: 306–315. 10.1016\u002Fj.psychres.2006.10.004\nGrover S, Avasth A, Chakrabart S, Bhansali A, Kulhara P: Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta psychiatr Scand 2005, 112: 55–63.\nThe Department of Mental Health MoPH: Annual report. Bkk: Department of Mental Health; 2008.\nPharmacoeconomic modelling in schizophrenia: trap or support for decision makers [http:\u002F\u002Fwww.rees-france.com\u002Fen\u002Farticle.php3?id_article=470]\nLeucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 2009, 373: 31–41. 10.1016\u002FS0140-6736(08)61764-X\nKongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P: Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidone. J Med Assoc Thai 2005, 88: 1267–1277.\nMartin JLR, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E: Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 2006, 21: 11. 10.1016\u002Fj.eurpsy.2005.09.009\nMari JdJ, Razzouk D, Thara R, Eaton J, Thornicroft G: Packages of care for schizophrenia in low- and middle-income countries. PLoS Med 2009, 6: 1–8.\nPatterson TL, Leeuwenkamp OR: Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res 2008, 100: 108–119. 10.1016\u002Fj.schres.2007.12.468\nTaylor T, Killaspy H, Wright C, Turton P, White S, Kallert T, Schuster M, Cervilla J, Brangier P, Raboch J, et al.: A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems. BMC Psychiatry 2009, 9: 55. 10.1186\u002F1471-244X-9-55\nTan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray C: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.\nChisholm D: Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization. World Psychiatry 2005, 4: 37–44.\nPhanthunane P, Chaipornsupaisan W, Vos T: A survey of severity, quality of life and current treatment patterns in people with schizophrenia in Thailand 2008. Bangkok: SPICE project; 2008.\nGold MR, Siegal JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. New York: Oxford University Press, Inc.; 1996.\nMagnus A, Carr V, Mihalopoulos C, Carter R, Vos T: Assessing cost-effectiveness of drug interventions for schizophrenia. Australian and New Zealand Journal of Psychiatry 2005, 39: 44–54.\nDeeks JJ, Altman DG, Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. Edited by: Egger M, Smith GD, Altman D. London: BMJ Publishing Group; 2001:211–228.\nHaby MM, Carter R, Mihalopoulos C, Magnus A, Sanderson K, Andrews G, Vos T: Assessing cost-effectiveness - mental health: introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004, 38: 569–578.\nDuggan LFM, Rathbone J, Dardennes R, El-Dosoky A, Indran S: Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005.\nEssali AA-HHN, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009.\nHunter RHJC, Kennedy E, Gilbody SM, Song F: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003.\nIrving CBAC, Lawrie S: Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006.\nPekkala E, Merinder L: Psychoeducation for Schizophrenia. In Cochrane Database of Systematic Review. John Wiley & Sons, Ltd; 2002.\nPharoah F, Marit J, Rathbone J, Wong W: Family intervention for schizophrenia. In Cochrane Database of Systematic Reviews. John Wilet & Son, Ltd; 2006.\nPhanthunane P, Vos T, Whiteford H, Bertram M: Health outcomes of schizophrenia in Thailand: Health care provider and patient perspectives. Asian Journal of Psychiatry 2010, 3: 200–205. 10.1016\u002Fj.ajp.2010.09.004\nStouthard ME, Essink-Bot M-L, Bonsel GJ, Barendregt JJ, Kramer PGN, Water HPAvd, Schepers LJG, Maas PJv: Disability weights for diseases in the Netherland. Rotterdam: Department of Public Health, Erasmus University Rotterdam; 1997.\nHarris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry 1997, 170: 205–228. 10.1192\u002Fbjp.170.3.205\nMunro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R: Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. 1999,175(576–580):576–580.\nHarris EC, Barraclough B: Excess mortality of mental disorder. 1998,173(11–53):11–53.\nLacro JPDL, Dolder CR, et al.: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63: 892–909. 10.4088\u002FJCP.v63n1007\nPrukkanone B, Vos T, Burgess P, Chaiyakunapruk N, Bertram M: Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. BMC Psychiatry 2010, 10: 64. 10.1186\u002F1471-244X-10-64\nMatthew JB, Paul AN, Emmeline L: Antipsychotic Medication Adherence in Schizophrenia. The Psychiatric clinics of North America 2007, 30: 437. 10.1016\u002Fj.psc.2007.04.002\nValenstein M, Blow F, Copeland L, McCarthy J, Zeber J, Gillon L, Bingham C, Stavenger T: Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors. Schizophrenia Bulletin 2004, 30: 255.\nGrunder G, Hippius H, Carlsson A: The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009, 8: 197–202. 10.1038\u002Fnrd2806\nLeucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361: 1581–1589. 10.1016\u002FS0140-6736(03)13306-5\nAdams CE, Awad G, Rathbone J, Thornley B: Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007.\nCheng L-Y, Chan S: Psychoeducation Program for Chinese Family Carers of Members With Schizophrenia. West J Nurs Res 2005, 27: 583–599. 10.1177\u002F0193945905275938\nMatichon: The happiness of people with mental disorder-cheaper medications. Matichononline; 2009.\nVos T, Haby MM, Magnus A, Mihalopoulos C, Andrews G, Carter R: Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Australian and New Zealand Journal of Psychiatry 2005, 39: 701–712.\nTandon R, Targum SD, Nasrallah HA, Ross R: Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Journal of Psychiatric Practice 2006, 12: 348–363. 10.1097\u002F00131746-200611000-00003\nChantarasak S: Study of safety and outcomes of clozapine for treatmetn of schizophrenia at Sruthunya hospital. Journal of Mental Health of Thailand 2003, 9: 82.\nKelvin MT, Fung HWHT, Patrick W Corrigan: Self-stigma of people with schizophrenia as predictor of their adherence to psychosocial treatment. Psychiatric Rehabilitation Journal 2008, 32: 95–104. 10.2975\u002F32.2.2008.95.104\nHeeg BMS, Damen J, Buskens E, Caleo S, Frank de C, van Hout BA: Modelling Approaches: The Case of Schizophrenia. PharmacoEconomics 2008, 26: 633–648. 10.2165\u002F00019053-200826080-00002\nVoruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A: Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002, 57: 201. 10.1016\u002FS0920-9964(01)00309-7\nRosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J: Does switching to a new antipsychotic improve outcomes?: Data from the CATIE trial. Schizophr Res 2009, 107: 22–29. 10.1016\u002Fj.schres.2008.09.031\nObradovic M, Mrhar A, Kos M: Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007, 61: 1979–1988. 10.1111\u002Fj.1742-1241.2007.01431.x\nLindner LM, Marasciulo AC, Farias MR, Grohs GEM: Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian healthcare system. Rev Saúde Pública 2009, 43: 62–69.\nCooper D, Moisan J, Abdous B, Grégoire JP: A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. Can J Clin Pharmacol 2008, 15: 385–397.\nChisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, Ayuso-Mateos J-L, Saxena S: Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. WHO bulletin 2008, 86: 542–551.\nAllison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. Am J Psychiatry 1999, 156: 1686–1696.\nJablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C: Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Australian and New Zealand Journal of Psychiatry 2000, 34: 221.\nSavilla K, Kettler L, Galletly C: Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Australian and New Zealand Journal of Psychiatry 2008, 42: 496–504. 10.1080\u002F00048670802050512\nNarvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL: Subjective and objective quality of life in schizophrenia. Schizophr Res 2008, 98: 201–208. 10.1016\u002Fj.schres.2007.09.001\nSitzer DITEW, Patterson TL, Jeste DV: Multivariate predictors of social skills performance in middle-aged and older out-patients with schizophrenia spectrum disorders. Psychological medicine 2008, 38: 755–763.\nTiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). The Lancet 2009, 374: 620–627. 10.1016\u002FS0140-6736(09)60742-X",{"EN":350},"Information on cost-effectiveness of interventions to treat schizophrenia can assist health policy decision making, particularly given the lack of health resources in developing countries like Thailand. This study aims to determine the optimal treatment package, including drug and non-drug interventions, for schizophrenia in Thailand. A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted life years. We evaluated intervention benefit by estimating a change in disease severity, taking into account potential side effects. Intervention costs included outpatient treatment costs, hospitalization costs as well as time and travel costs of patients and families. Uncertainty was evaluated using Monte Carlo simulation. A sensitivity analysis of the expected range cost of generic risperidone was undertaken. Generic risperidone is more cost-effective than typicals if it can be produced for less than 10 baht per 2 mg tablet. Risperidone was the cheapest treatment with higher drug costs offset by lower hospital costs in comparison to typicals. The most cost-effective combination of treatments was a combination of risperidone (dominant intervention). Adding family intervention has an incremental cost-effectiveness ratio of 1,900 baht\u002FDALY with a 100% probability of a result less than a threshold for very cost-effective interventions of one times GDP or 110,000 baht per DALY. Treating the most severe one third of patients with clozapine instead of risperidone had an incremental cost-effectiveness ratio of 320,000 baht\u002FDALY with just over 50% probability of a result below three times GDP per capita. There are good economic arguments to recommend generic risperidone as first line treatment in combination with family intervention. As the uncertainty interval indicates the addition of clozapine may be dominated and there are serious side effects, treating severe patients with clozapine is advisable only for patients who do not respond to risperidone and only in the presence of a stricter side effect monitoring system than currently exists.",{"EN":352},"Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia",{"VOID":354},"10.1186\u002F1478-7547-9-6","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002F1478-7547-9-6",[357,392,411,433],{"id":358,"sortIndex":19,"researcher":18,"roles":359,"affiliations":360,"properties":389},"c7dc70f5-853e-4a4d-a409-9c7cd333eba7",[126],[361,371,381],{"id":362,"sortIndex":257,"affiliation":363,"properties":370},"9330b363-9293-4c43-8a11-e0ee996e0314",{"id":364,"createTime":365,"updateTime":365,"relativeEntities":366,"slug":18,"properties":367,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a1a70f2e-7493-4330-8381-52b743999ee2","2024-01-21T02:35:08.229+00:00",[],{"title":368},{"VI":369},"Faculty of Management and Information Sciences, Naresuan University, Phitsanulok, Thailand",{},{"id":372,"sortIndex":94,"affiliation":373,"properties":380},"101b682d-0cb5-4f1f-8bf8-f4d4400f2a97",{"id":374,"createTime":375,"updateTime":375,"relativeEntities":376,"slug":18,"properties":377,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a1f3e665-d12b-43c4-9d43-fd246733ca90","2023-12-11T15:42:11.992+00:00",[],{"title":378},{"VI":379},"School of Population Health, The University of Queensland, Herston, Australia",{},{"id":18,"sortIndex":19,"affiliation":382,"properties":18},{"id":383,"createTime":384,"updateTime":384,"relativeEntities":385,"slug":18,"properties":386,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f6117381-1fd3-468d-bf82-45a0daccb6c4","2024-01-21T02:35:08.165+00:00",[],{"title":387},{"VI":388},"Setting Priorities Using Information on Cost-Effectiveness (SPICE) project, Ministry of Public Health, Nonthaburi, Thailand",{"title":390},{"VI":391},"Pudtan Phanthunane",{"id":393,"sortIndex":94,"researcher":18,"roles":394,"affiliations":395,"properties":408},"99476ede-64a2-47ed-bd4a-d1f67aaa2edc",[126],[396,401],{"id":18,"sortIndex":19,"affiliation":397,"properties":18},{"id":383,"createTime":384,"updateTime":384,"relativeEntities":398,"slug":18,"properties":399,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":400},{"VI":388},{"id":402,"sortIndex":94,"affiliation":403,"properties":407},"5a734993-a74a-48da-991f-bf6a270dbde7",{"id":374,"createTime":375,"updateTime":375,"relativeEntities":404,"slug":18,"properties":405,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":406},{"VI":379},{},{"title":409},{"VI":410},"Theo Vos",{"id":412,"sortIndex":257,"researcher":18,"roles":413,"affiliations":414,"properties":430},"ce8690d4-6208-4fe1-8276-dcd11e1c6178",[126],[415,425],{"id":416,"sortIndex":94,"affiliation":417,"properties":424},"b3111581-55b7-4c62-84b8-bca289b6e707",{"id":418,"createTime":419,"updateTime":419,"relativeEntities":420,"slug":18,"properties":421,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"18720c48-6a8e-4d49-84a7-59cf6c69adbf","2023-12-24T22:50:15.429+00:00",[],{"title":422},{"VI":423},"Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Australia",{},{"id":18,"sortIndex":19,"affiliation":426,"properties":18},{"id":374,"createTime":375,"updateTime":375,"relativeEntities":427,"slug":18,"properties":428,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":429},{"VI":379},{"title":431},{"VI":432},"Harvey Whiteford",{"id":434,"sortIndex":270,"researcher":18,"roles":435,"affiliations":436,"properties":449},"69f89546-f952-443b-82c7-277324ecd1b5",[126],[437,442],{"id":18,"sortIndex":19,"affiliation":438,"properties":18},{"id":383,"createTime":384,"updateTime":384,"relativeEntities":439,"slug":18,"properties":440,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":441},{"VI":388},{"id":443,"sortIndex":94,"affiliation":444,"properties":448},"72204299-51ab-4b4a-ac9c-378939e8049e",{"id":364,"createTime":365,"updateTime":365,"relativeEntities":445,"slug":18,"properties":446,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":447},{"VI":369},{},{"title":450},{"VI":451},"Melanie Bertram",{"url":355,"publisher":453,"properties":480},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":454,"slug":10,"properties":455,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":458,"manageAffiliations":459,"indexDatabases":460,"url":91,"thumbnailPath":18,"statistic":475,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":456,"title":457},{"VOID":13},{"EN":15},[],[],[461,468],{"id":54,"indexDatabase":462,"url":67,"indexYears":68,"academicFieldIds":467,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":463,"label":464,"description":465,"key":64,"publicationTags":466,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":469,"url":88,"indexYears":18,"academicFieldIds":474,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":470,"label":471,"description":472,"key":84,"publicationTags":473,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":476,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":477,"totalCitation":19,"totalCitationByYear":478,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":479,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":481,"pages":483},{"VOID":482},"9",{"VOID":337},"2011-05-13",2011,{"id":487,"createTime":488,"updateTime":488,"relativeEntities":489,"slug":490,"properties":491,"entityType":118,"verifyStatus":119,"verifyTime":488,"verifyNote":120,"syncStatus":17,"languages":507,"translateLanguages":18,"viewCount":19,"primaryUrl":509,"fullTextUrl":18,"authors":510,"publicationType":153,"publisherRelationship":631,"citationCount":664,"citationInfo":665,"publishDate":667,"publishYear":668,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":669,"isForceReanalyzing":189},"61b4cbad-b62a-404a-a908-9a836bf7f68b","2024-08-31T23:42:19.853+00:00",[],"Analysis-of-the-gap-in-PCR-monitoring-availability-for-patients-with-chronic-myeloid-leukemia-in-60-low-and-middle-income-countries",{"mag":492,"keywords":494,"pmc":495,"openalex":497,"abstract":499,"title":501,"pm":503,"doi":505},{"VOID":493},"3123338400",{},{"VOID":496},"7953726",{"VOID":498},"W3123338400",{"EN":500},"\u003Cjats:title>Abstract\u003C\u002Fjats:title>\u003Cjats:sec>\n                \u003Cjats:title>Purpose\u003C\u002Fjats:title>\n                \u003Cjats:p>To estimate the resource gap in the polymerase chain reaction (PCR) monitoring for patients with chronic myeloid leukemia (CML) in low- and middle-income countries (LMICs).\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Methods\u003C\u002Fjats:title>\n                \u003Cjats:p>We developed a model of demand and supply of PCR monitoring of CML patients in 60 LMICs. PCR testing was assumed to use Cepheid’s GeneXpert® \u003Cjats:sup>IV\u003C\u002Fjats:sup> system. We included costs of GeneXpert® instruments, uninterrupted power supplies, warranties, calibration kits, test cartridges, and shipping. We calculated the country-specific monetary gap in PCR monitoring, stratified by country priority defined as the availability of tyrosine kinase inhibitors (TKIs) through The Max Foundation initiatives.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Results\u003C\u002Fjats:title>\n                \u003Cjats:p>The 5-year gap in PCR monitoring was $29.1 million across all countries, 22% ($6.4 million) in countries with all five TKIs available, 20% ($5.7 million) in countries with four TKIs available, 50% ($14.5 million) in countries with three TKIs available, 8% ($2.2 million) in countries with two TKIs available, and 1% ($0.3 million) in countries with one TKI available. The gap was highest in South Asia (52%; $15.1 million) and lowest in Latin America (6%; $1.9 million). Excluding labor costs, the bulk of the resource needs (86%; $25.2 million) were for procurement of BCR-ABL cartridges.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>\u003Cjats:sec>\n                \u003Cjats:title>Conclusion\u003C\u002Fjats:title>\n                \u003Cjats:p>Removing the 5-year gap in PCR monitoring capacity for CML in LMICs will require the mobilization of significant resources and will likely lead to better treatment outcomes and reduced treatment costs through optimization of treatment, discontinuation of therapy in appropriate patients, and facilitation of clinical research. Development of streamlined monitoring guidelines for resource-limited countries should be considered.\u003C\u002Fjats:p>\n              \u003C\u002Fjats:sec>",{"EN":502},"Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries",{"VOID":504},"33712039",{"VOID":506},"10.1186\u002Fs12962-021-00271-x",[508],"EN","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-021-00271-x",[511,533,555,575,592,614],{"id":512,"sortIndex":257,"researcher":18,"roles":513,"affiliations":514,"properties":526},"0c21002c-0f49-49a7-9601-88de8a67a708",[],[515],{"id":516,"sortIndex":19,"affiliation":517,"properties":18},"b0954d67-872d-4d78-aa45-7065b59cc317",{"id":518,"createTime":519,"updateTime":520,"relativeEntities":521,"slug":522,"properties":523,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"15f31e8b-28f7-41f2-a3d6-d549ec267241","2023-12-06T21:32:01.597+00:00","2024-12-28T23:07:19.325+00:00",[],"Fred-Hutchinson-Cancer-Research-Center-Seattle-WA-USA",{"title":524},{"VI":525},"Fred Hutchinson Cancer Research Center, Seattle, WA, USA",{"openalex":527,"orcid":529,"title":531},{"VOID":528},"A5089541690",{"VOID":530},"https:\u002F\u002Forcid.org\u002F0000-0002-1618-230X",{"EN":532},"Jerald P. Radich",{"id":534,"sortIndex":19,"researcher":18,"roles":535,"affiliations":536,"properties":548},"9450fbaf-7f2a-4bc5-b898-d04ecc6e052c",[],[537],{"id":538,"sortIndex":19,"affiliation":539,"properties":18},"8d810620-5891-47d3-8d15-8a387ae2cfa4",{"id":540,"createTime":541,"updateTime":542,"relativeEntities":543,"slug":544,"properties":545,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0a49f0dd-53ae-49d1-b921-86c6de9fdfdd","2024-01-17T04:24:36.576+00:00","2025-06-11T23:12:12.919+00:00",[],"Department-of-Epidemiology-School-of-Public-Health-University-of-Washington-Seattle-USA",{"title":546},{"VI":547},"Department of Epidemiology, School of Public Health University of Washington, Seattle, USA",{"openalex":549,"orcid":551,"title":553},{"VOID":550},"A5001454179",{"VOID":552},"https:\u002F\u002Forcid.org\u002F0000-0003-1677-4281",{"EN":554},"SD Rowley",{"id":556,"sortIndex":209,"researcher":18,"roles":557,"affiliations":558,"properties":570},"f3318494-a310-4da8-833a-f183ea2c199d",[],[559],{"id":560,"sortIndex":19,"affiliation":561,"properties":18},"993853f4-22cd-4362-9929-ebb4496f43d9",{"id":562,"createTime":563,"updateTime":564,"relativeEntities":565,"slug":566,"properties":567,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3ac05cf8-31f9-4876-b3af-0b019fa835df","2024-04-11T16:48:03.661+00:00","2024-08-31T23:42:19.927+00:00",[],"The-Max-Foundation-Seattle-WA-USA",{"title":568},{"EN":569},"The Max Foundation, Seattle, WA, USA",{"openalex":571,"title":573},{"VOID":572},"A5089030878",{"EN":574},"Irina Usherenko",{"id":576,"sortIndex":270,"researcher":18,"roles":577,"affiliations":578,"properties":585},"b674b65c-9a7c-4004-8cc1-456957358af6",[],[579],{"id":580,"sortIndex":19,"affiliation":581,"properties":18},"c0b55530-4c2d-4618-9816-1d25d1cc3768",{"id":562,"createTime":563,"updateTime":564,"relativeEntities":582,"slug":566,"properties":583,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":584},{"EN":569},{"openalex":586,"orcid":588,"title":590},{"VOID":587},"A5033348428",{"VOID":589},"https:\u002F\u002Forcid.org\u002F0000-0002-1309-8356",{"EN":591},"Ann Kim Novakowski",{"id":593,"sortIndex":594,"researcher":18,"roles":595,"affiliations":596,"properties":607},"d7ea2211-e09c-4a85-ab7c-a757c42423a8",5,[],[597],{"id":598,"sortIndex":19,"affiliation":599,"properties":18},"b7530918-f506-420e-a4ba-9371de575ced",{"id":600,"createTime":601,"updateTime":601,"relativeEntities":602,"slug":603,"properties":604,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"76ad4a7b-653d-476d-8733-e7cee729841b","2024-08-31T23:42:20.075+00:00",[],"Global-Medicines-Program-Department-of-Global-Health-School-of-Public-Health-University-of-Washington-Seattle-USA",{"title":605},{"EN":606},"Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, USA",{"openalex":608,"orcid":610,"title":612},{"VOID":609},"A5036106727",{"VOID":611},"https:\u002F\u002Forcid.org\u002F0000-0003-3834-7141",{"EN":613},"Joseph B. Babigumira",{"id":615,"sortIndex":94,"researcher":18,"roles":616,"affiliations":617,"properties":624},"2044edf7-7b27-4cbd-b9c6-9e161b3c000e",[],[618],{"id":619,"sortIndex":19,"affiliation":620,"properties":18},"d0e06762-31d0-42f8-b45d-773c98de46da",{"id":562,"createTime":563,"updateTime":564,"relativeEntities":621,"slug":566,"properties":622,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":623},{"EN":569},{"openalex":625,"orcid":627,"title":629},{"VOID":626},"A5040107887",{"VOID":628},"https:\u002F\u002Forcid.org\u002F0000-0002-4544-9253",{"EN":630},"Pat Garcia-Gonzalez",{"url":18,"publisher":632,"properties":659},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":633,"slug":10,"properties":634,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":637,"manageAffiliations":638,"indexDatabases":639,"url":91,"thumbnailPath":18,"statistic":654,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":635,"title":636},{"VOID":13},{"EN":15},[],[],[640,647],{"id":54,"indexDatabase":641,"url":67,"indexYears":68,"academicFieldIds":646,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":642,"label":643,"description":644,"key":64,"publicationTags":645,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":648,"url":88,"indexYears":18,"academicFieldIds":653,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":649,"label":650,"description":651,"key":84,"publicationTags":652,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":655,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":656,"totalCitation":19,"totalCitationByYear":657,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":658,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":660,"issue":662},{"VOID":661},"19",{"VOID":663},"1",7,{"total":664,"publishYear":18,"statisticByYear":666},{"2022":257,"2023":209,"2024":94},"2021-12-01",2021,[670,674,678,682,686,690,694,698,701,705,708,711,715,719,723,727],{"id":18,"text":671,"url":18,"identifiers":672},"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–9.",{"doi":673},"10.1182\u002Fblood-2015-01-617993",{"id":18,"text":675,"url":18,"identifiers":676},"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.",{"doi":677},"10.1182\u002Fblood-2013-05-501569",{"id":18,"text":679,"url":18,"identifiers":680},"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:1108–35.",{"doi":681},"10.6004\u002Fjnccn.2018.0071",{"id":18,"text":683,"url":18,"identifiers":684},"Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J, Wang J, Tsongalis GJ, Belloni D, Chan D, Eshleman JR, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53:1593–600.",{"doi":685},"10.1373\u002Fclinchem.2007.085472",{"id":18,"text":687,"url":18,"identifiers":688},"Stevens WS, Scott L, Noble L. Gous N. Dheda K: Impact of the GeneXpert MTB\u002FRIF Technology on Tuberculosis Control. Microbiol Spectr; 2017.10.1128\u002Fmicrobiolspec.TBTB2-0040-2016.",{"doi":689},"10.1128\u002Fmicrobiolspec.TBTB2-0040-2016",{"id":18,"text":691,"url":18,"identifiers":692},"Wexler C, Nazir N, Maloba M, Brown M, Goggin K, Gautney B, Maosa N, Babu S, Muchoki E, Mabachi N, et al. Programmatic evaluation of feasibility and efficiency of at birth and 6-week, point of care HIV testing in Kenyan infant. PLoS ONE. 2020;15:e0240621.",{"doi":693},"10.1371\u002Fjournal.pone.0240621",{"id":18,"text":695,"url":18,"identifiers":696},"Garcia-Gonzalez P, Boultbee P, Epstein D. Novel humanitarian aid program: the glivec international patient assistance program—lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries. J Glob Oncol. 2015;1:37–45.",{"doi":697},"10.1200\u002FJGO.2015.000570",{"id":18,"text":699,"url":18,"identifiers":700},"Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries. https:\u002F\u002Fwww.novartis.com\u002Fnews\u002Fmedia-releases\u002Fnovartis-and-max-foundation-transform-pioneering-cancer-access-program-people. Accessed 23 Jan 2018.",{},{"id":18,"text":702,"url":18,"identifiers":703},"Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, Wang Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.",{"doi":704},"10.1186\u002Fs40164-020-00170-6",{"id":18,"text":706,"url":18,"identifiers":707},"Stop TB Department (2012) Buy-down agreement to reduce cost of Xpert MTB\u002FRIF cartridges by 40% for high-burden countries. http:\u002F\u002Fwww.stoptb.org\u002Fwg\u002Fnew_diagnostics\u002Fassets\u002Fdocuments\u002FNews_XpertPrice_21Aug12.pdf. Accessed 24 Jan 2018.",{},{"id":18,"text":709,"url":18,"identifiers":710},"Public-Private Partnership Announces Immediate 40 Percent Cost Reduction for Rapid TB Test | The Bill & Melinda Gates Foundation. Press Release. August 6th 2012. https:\u002F\u002Fwww.gatesfoundation.org\u002FMedia-Center\u002FPress-Releases\u002F2012\u002F08\u002FPublicPrivate-Partnership-Announces-Immediate-40-Percent-Cost-Reduction-for-Rapid-TB-Test. Accessed 23 Jan 2019.",{},{"id":18,"text":712,"url":18,"identifiers":713},"Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, Zhan FM, Liu MB. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin Drug Investig. 2018;38:79–86.",{"doi":714},"10.1007\u002Fs40261-017-0587-z",{"id":18,"text":716,"url":18,"identifiers":717},"Kulpeng W, Sompitak S, Jootar S, Chansung K, Teerawattananon Y. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Ther. 2014;36:534–43.",{"doi":718},"10.1016\u002Fj.clinthera.2014.02.008",{"id":18,"text":720,"url":18,"identifiers":721},"Wu B, Liu M, Li T, Lin H, Zhong H. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: a CHEERS-compliant article. Medicine. 2017;96:e7445.",{"doi":722},"10.1097\u002FMD.0000000000007445",{"id":18,"text":724,"url":18,"identifiers":725},"Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. J Med Econ. 2016;19:445–61.",{"doi":726},"10.3111\u002F13696998.2015.1126285",{"id":18,"text":728,"url":18,"identifiers":729},"Romero M, Chávez D, De Los RM, Alvis-Guzmán N. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014;34:48–59.",{"doi":730},"10.7705\u002Fbiomedica.v34i1.1446",{"id":732,"createTime":733,"updateTime":734,"relativeEntities":735,"slug":736,"properties":737,"entityType":118,"verifyStatus":119,"verifyTime":734,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":746,"fullTextUrl":18,"authors":747,"publicationType":153,"publisherRelationship":851,"citationCount":18,"citationInfo":18,"publishDate":884,"publishYear":885,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"5bc02ae3-7ea9-48a9-afe1-85e4fde0243a","2024-01-11T11:58:40.197+00:00","2025-02-17T23:41:55.623+00:00",[],"Modeling-the-Cost-effectiveness-of-Esophageal-Cancer-Screening-in-China",{"references":738,"abstract":740,"title":742,"doi":744},{"VOID":739},"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA oncol. 2015;1(4):505–27.\nNapier KJ, Scheerer M, Misra S. Esophageal cancer: a Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112–20.\nGBD 2017 Disease injury Incidence Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.\nArnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7.\nChen WQ, Zheng RS, Zhang SW, Zeng HM, Zuo TT, Xia CF, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017;29(1):1–10.\nChinese Society of Gastroenterology gastrointestinal cancer group CSoDEedatgadpg. Expert consensus on china screening, diagnosis and treatment of early-stage and precancerous lesion of esophageal squamous cell carcinoma. Chin J Intern Med. 2016;55(1):73–85.\nReid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101.\nEngel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404–13.\nHu GY, Dong P, Yan WQ, Xi Q. Discovery approach and economic burden of six kinds of common cancers patients in Beijing. Cancer Res Prev Treat. 2015;42(2):171–6.\nPennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet (London, England). 2013;381(9864):400–12.\nDai M, Shi JF, Li N. Design and expected goal of early diagnosis and treatment of cancer project in Chinese cities. Chin J Prev Med. 2013;47(2):179–82.\nHealth disease Prevention and Control Bureau, Cancer Diagnosis and Treatment Project Expert Committee. Guideline for Early diagnosis and treatment of cancer. Beijing: Beijing People’s Medical Publishing House; 2011.\nStephen BE, David RB, Carolyn CC, April GF, Frederick LG, Yrotti A. AJCC cancer staging manual. Am Joint Committ Cancer. 2010;2010:103–15.\nLi YY, Du LB, Hu XQ, Jaiswal S, Gu SY, Gu YX, et al. A suggested framework for conductiong esophageal cancer screening in China. J Dig Dis. 2019;19:722–9.\nWei WQ, Chen ZF, He YT, Feng H, Hou J, Lin DM, et al. Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China. J Clin Oncol. 2015;33(17):1951–7.\nBarret M, Prat F. Diagnosis and treatment of superficial esophageal cancer. Ann Gastroenterol. 2018;31(3):256–65.\nNagami Y, Ominami M, Shiba M, Minamino H, Fukunaga S, Kameda N, et al. The five-year survival rate after endoscopic submucosal dissection for superficial esophageal squamous cell neoplasia. Dig Liver Dis. 2017;49(4):427–33.\nPauthner M, Haist T, Mann M, Lorenz D. Surgical therapy of early carcinoma of the esophagus. Viszeralmedizin. 2015;31(5):326–30.\nWang G, Hao C, Wei W. Longterm survival rate of precancerous lesions and early esophageal cancers after endoscopic mucosal resection. Chin J Digest Endosc. 2008;25(11):584–6.\nDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.\nWHO-CHOICE. Cost-effectiveness threshold. http:\u002F\u002Fwww.who.int\u002Fchoice\u002Fcosts\u002FCER_thresholds\u002Fen\u002Findex.html. Accessed 16 March, 2012.\nHealth Commission of Zhejiang Province. Price of medical services in provincial public hospitals. http:\u002F\u002Fwww.zjwjw.gov.cn\u002Fart\u002F2017\u002F5\u002F22\u002Fart_1267707_452.html. Accepted 22 May 2017.\nOrganization for Economic Co-operation and Development(OECD) (2017) PPPs and exchange rates: purchasing power parities for GDP. https:\u002F\u002Fstatsoecdorg\u002FIndexaspx?datasetcode=SNA_Table4. Accessed 16 Jul 2017.\nNational Bureau of Statistics of the People’s Republic of China. Health service price index. http:\u002F\u002Fwww.stats.gov.cn\u002Ftjsj\u002Fndsj\u002F2018\u002Findexch.htm.\nWang Y, Shi J, Du L, Huang H, Wang L, Zhu J, et al. Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: a multicenter cross-sectional study. Thorac Cancer. 2020;11(4):1076–89.\nWang H, Pan Y, Guo C, Li F, Xu R, Liu M, et al. Health-related quality of life among rural residents aged 45–69 years in Hua County, Henan Province, China: results of ESECC Trial for esophageal cancer screening with endoscopy. Chin J Cancer Res. 2018;30(2):240–53.\nDoherty MK, Leung Y, Su J, Naik H, Patel D, Eng L, et al. Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study. Dis Esophagus. 2018;31:12.\nSmith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care. 2001;17(2):236–43.\nCommittee of Chinese society of pharmaceutical economics. China Guidelines for Pharmacoecomonic Evaluations (2019 Edition).\nMao WM, Jin F, Yu M. Zhejiang cancer registry annual report. Hangzhou: Zhejiang Science and Technology Press; 2016.\nMiller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Mak. 1994;14(1):52–8.\nWhang SJ, Zhang LW, Wen DG, Li YS, Yu WF, Wang XL, et al. Analysis of endoscopic screening for the natural history of precancerous lesions in esophagus and cardia. Chian Cancer. 2007;34(7):370–3.\nWen D, Zhang L, Wang X, Li Y, Ma C, Liu X, et al. A 55-year surveillance of esophageal and gastric cardia precursors after a population-based screening in China. J Gastroenterol Hepatol. 2015;30(12):1720–5.\nWen DG, Zhang LW, Wang XL, Wen X, Yang Y, Chen YT, et al. Heterogeneity in esophageal and gastric cardia precursor progression during six-year endoscopic surveillance after population-based screening in a Chinese high-risk region. Thorac Cancer. 2017;8(4):328–36.\nChinese Academy of Medical Sciences, Esophageal Cancer Prevention and Treatment Research Team in Linxian. Outcome of esophageal epithelial hyperplasia: summary of follow-up by cytological examination. Cancer Res Prev Treat. 1974;1:42–6.\nHe YL, Zhang WJ, Liu YQ. Analysis of endoscopic screening for upper digestive tract cancer in Gaotai County, 2011–2015. China Cancer. 2017;26(6):447–51.\nLh L. Analysis of esophageal cancer\u002Fcardia cancer screening with iodine staining method throug endoscopy and esophageal atypical hyperplasia fellow-up in XianJu [Maser thesis]. Zhejiang: Zhejiang University; 2014.\nWang LD, Hq G. The development of esophageal epithelial hyperplasia-six years’ follow-up of 66 subjects. J Henan Med Univ. 1991;26(4):328–30.\nDawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 1994;74(6):1686–92.\nWang LD, Yang HH, Fan ZM, Lu XD, Wang JK, Liu XL, et al. Cytological screening and 15 years’ follow-up (1986–2001) for early esophageal squamous cell carcinoma and precancerous lesions in a high-risk population in Anyang County, Henan Province, Northern China. Cancer Detect Prev. 2005;29(4):317–22.\nWang M. A prospective cohort study of the distribution and the progress rate of precancerous lesions of Eesophageal squamous cell carcinoma in high-risk areas of china. Chinese academy of medical sciences, Peking union medical college Master’s thesis. 2016.\nTao DM, Xu YZ, Gu YK, Wang DY, Wang XH, Gh Y. A study of the carcinogenesis time and incidence of carcinoma in 46161 cases with normal and Hyperplastic esophageal epithelia. Cancer Prev Res. 1997;1997:155–6.\nPopulation Census Office of the State Council, Population Statistics Department of National Bureau of Statistics. Tabulation on the 2010 population census of the people’s republic of China. 2012. http:\u002F\u002Fwww.stats.gov.cn\u002Ftjsj\u002Fpcsj\u002Frkpc\u002F6rp\u002Findexch.htm. Accessed 1 Dec 2012.\nChen WQ, Li N, Shi JF, Chen HD, Li J, et al. Progress of cancer screening program in urban China. China Cancer. 2019;28(1):23–5.\nDawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, et al. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer. 1998;83(2):220–31.\nHashimoto CL, Iriya K, Baba ER, Navarro-Rodriguez T, Zerbini MC, Eisig JN, et al. Lugol’s dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am J Gastroenterol. 2005;100(2):275–82.\nNakagawa K, Koike T, Iijima K, Shinkai H, Hatta W, Endo H, et al. Comparison of the long-term outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan. Am J Gastroenterol. 2014;109(3):348–56.\nYamashina T, Ishihara R, Nagai K, Matsuura N, Matsui F, Ito T, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol. 2013;108(4):544–51.\nTsujii Y, Nishida T, Nishiyama O, Yamamoto K, Kawai N, Yamaguchi S, et al. Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms: a multicenter retrospective cohort study. Endoscopy. 2015;47(9):775–83.\nDaoud DC, Suter N, Durand M, Bouin M, Faulques B, von Renteln D. Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries: a systematic review and meta-analysis. World J Gastroenterol. 2018;24(23):2518–36.\nKonda VJ, Ross AS, Ferguson MK, Hart JA, Lin S, Naylor K, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6(2):159–64.\nRice TW, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, et al. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Dis Esoph. 2016;29(7):715–23.\nGockel I, Sgourakis G, Lyros O, Polotzek U, Schimanski CC, Lang H, et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011;5(3):371–84.\nChan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100(4):456–64.\nChen SB, Weng HR, Wang G, Yang JS, Yang WP, Liu DT, et al. Surgical treatment for early esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2013;14(6):3825–30.\nFujita H, Sueyoshi S, Yamana H, Shinozaki K, Toh U, Tanaka Y, et al. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg. 2001;25(4):424–31.\nStein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg. 2000;232(6):733–42.\nMitsuo T, Hiroshi Y, Shoichi K, Naoki H, Dipok KD, Shun’ichi A, et al. Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg. 1997;174:49–53.\nvan Sandick JW, van Lanschot JJ, ten Kate FJ, Offerhaus GJ, Fockens P, Tytgat GN, et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer. 2000;88(11):2429–37.\nYoshinaka H, Shimazu H, Fukumoto T, Baba M. Superficial esophageal carcinoma: a clinicopathological review of 59 cases. Am J Gastroenterol. 1991;86(10):1413–8.\nNatsugoe S, Baba M, Yoshinaka H, Kijima F, Shimada M, Shirao K, et al. Mucosal squamous cell carcinoma of the esophagus: a clinicopathologic study of 30 cases. Oncology. 1998;55(3):235–41.\nSgourakis G, Gockel I, Lang H. Endoscopic and surgical resection of T1a\u002FT1b esophageal neoplasms: a systematic review. World J Gastroenterol. 2013;19(9):1424–37.\nKarstens KF, Izbicki JR, Reeh M. Does the margin matter in esophageal cancer. Dig Surg. 2018;35(3):196–203.\nKnight WRC, Zylstra J, Wulaningsih W, Van Hemelrijck M, Landau D, Maisey N, et al. Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. BJS Open. 2018;2(4):229–37.\nZou ZH, Liao XZ, Xu KK, Shi ZH, Zhu SL, Hf X. Analysis of screening results of 6400 urban lung cancer in high-risk groups. Pract Prev Med. 2016;23(5):593–4.\nSaddoughi SA, Reinersman JM, Zhukov YO, Taswell J, Mara K, Harmsen SW, et al. Survival after surgical resection of stage IV esophageal cancer. Ann Thorac Surg. 2017;103(1):261–6.\nRice TW, Ishwaran H, Hofstetter WL, Kelsen DP, Apperson-Hansen C, Blackstone EH, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\u002FUICC staging manuals. Dis Esoph. 2016;29(8):897–905.\nU.S. National cancer Institution(2019). Cancer Stat Fact Sheets: Esophageal Cancer. http:\u002F\u002Fseer.cancer.gov\u002Fstatfacts\u002Fhtml\u002Fesoph.html.\nChen ZL, Ren YH, Du XLL, Yang J, Shen YW, Li ST, et al. Incidence and survival differences in esophageal cancer among ethnic groups in the United States. Oncotarget. 2017;8(29):47037–51.",{"EN":741},"This study aimed to examine the cost-effectiveness of one-time standard endoscopic screening with Lugol’s iodine staining for esophageal cancer (EC) in China. A Markov decision analysis model with eleven states was built. Individuals aged 40 to 69 years were classified into six age groups in five-year intervals. Three different strategies were adopted for each cohort: (1) no screening; (2) one-time endoscopic screening with Lugol’s iodine staining with an annual follow-up for low-grade intraepithelial neoplasia (LGIN); and (3) one-time endoscopic screening with Lugol’s iodine staining without follow-up. Quality-adjusted life-years (QALYs) indicated the effectiveness of the model. The incremental cost-effectiveness ratio (ICER) was used as the evaluation indicator. Sensitivity analysis was performed to assess the robustness of the model. One-time screening with follow-up was the undominated strategy for individuals aged 40–44 and 45–49 years, which saved USD 10,942.57 and USD 6611.73 per QALY gained compared to nonscreening strategy. For those aged 50–69 years, the nonscreening scenarios were undominated. One-time screening without follow-up was the extended dominated strategy. Compared to screening strategies without follow-up, all the screening strategies with follow-up were more cost-effective, with the ICER increasing from 299.57 USD\u002FQALY for individuals aged 40–44 years to 1617.72 USD\u002FQALY for individuals aged 65–69 years. Probabilistic sensitivity analysis (PSA) supported the results of the base case analysis. One-time EC screening with follow-up targeting individuals aged 40–49 years was the most cost-effective strategy.",{"EN":743},"Modeling the Cost-effectiveness of Esophageal Cancer Screening in China",{"VOID":745},"10.1186\u002Fs12962-020-00230-y","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-020-00230-y",[748,763,778,790,803,815,827,839],{"id":749,"sortIndex":270,"researcher":18,"roles":750,"affiliations":751,"properties":760},"63f8a2a5-08ea-4157-88dc-77d64dd6a03a",[126],[752],{"id":18,"sortIndex":19,"affiliation":753,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":756,"slug":18,"properties":757,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2ae5c5c3-db7d-48ed-98cb-3cb401c1ccdb","2024-01-27T21:27:19.056+00:00",[],{"title":758},{"VI":759},"Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China",{"title":761},{"VI":762},"Yuxuan Gu",{"id":764,"sortIndex":94,"researcher":18,"roles":765,"affiliations":766,"properties":775},"d44bd245-213f-41b8-8238-5ffc57f19087",[126],[767],{"id":18,"sortIndex":19,"affiliation":768,"properties":18},{"id":769,"createTime":770,"updateTime":770,"relativeEntities":771,"slug":18,"properties":772,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2398021f-bc52-42bb-a6bb-04cedc620a3b","2024-01-11T11:58:40.226+00:00",[],{"title":773},{"VI":774},"Department of Cancer Prevention, Institute of Cancer Research and Basic Medical Science of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China",{"title":776},{"VI":777},"Lingbin Du",{"id":779,"sortIndex":664,"researcher":18,"roles":780,"affiliations":781,"properties":787},"ea0bd414-2f77-4b61-b6c8-dc704070e2dc",[126],[782],{"id":18,"sortIndex":19,"affiliation":783,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":784,"slug":18,"properties":785,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":786},{"VI":759},{"title":788},{"VI":789},"Hengjin Dong",{"id":791,"sortIndex":792,"researcher":18,"roles":793,"affiliations":794,"properties":800},"9e816c0b-4ce0-4f95-ba17-63e57c4467e8",6,[126],[795],{"id":18,"sortIndex":19,"affiliation":796,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":797,"slug":18,"properties":798,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":799},{"VI":759},{"title":801},{"VI":802},"Xueshan Sun",{"id":804,"sortIndex":19,"researcher":18,"roles":805,"affiliations":806,"properties":812},"84105c70-92a3-45b8-bacf-a739eaa03f63",[126],[807],{"id":18,"sortIndex":19,"affiliation":808,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":809,"slug":18,"properties":810,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":811},{"VI":759},{"title":813},{"VI":814},"Yuanyuan Li",{"id":816,"sortIndex":257,"researcher":18,"roles":817,"affiliations":818,"properties":824},"c91d7ac5-4142-4a8c-9195-1b0e0434a9a5",[126],[819],{"id":18,"sortIndex":19,"affiliation":820,"properties":18},{"id":769,"createTime":770,"updateTime":770,"relativeEntities":821,"slug":18,"properties":822,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":823},{"VI":774},{"title":825},{"VI":826},"Youqing Wang",{"id":828,"sortIndex":209,"researcher":18,"roles":829,"affiliations":830,"properties":836},"6bb2620e-72e5-40c0-a717-f77600974cab",[126],[831],{"id":18,"sortIndex":19,"affiliation":832,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":833,"slug":18,"properties":834,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":835},{"VI":759},{"title":837},{"VI":838},"Xuemei Zhen",{"id":840,"sortIndex":594,"researcher":18,"roles":841,"affiliations":842,"properties":848},"1265d39c-e890-4269-8bc5-c5ba532ea62a",[126],[843],{"id":18,"sortIndex":19,"affiliation":844,"properties":18},{"id":754,"createTime":755,"updateTime":755,"relativeEntities":845,"slug":18,"properties":846,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":847},{"VI":759},{"title":849},{"VI":850},"Xiaoqian Hu",{"url":746,"publisher":852,"properties":879},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":853,"slug":10,"properties":854,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":857,"manageAffiliations":858,"indexDatabases":859,"url":91,"thumbnailPath":18,"statistic":874,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":855,"title":856},{"VOID":13},{"EN":15},[],[],[860,867],{"id":54,"indexDatabase":861,"url":67,"indexYears":68,"academicFieldIds":866,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":862,"label":863,"description":864,"key":64,"publicationTags":865,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":868,"url":88,"indexYears":18,"academicFieldIds":873,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":869,"label":870,"description":871,"key":84,"publicationTags":872,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":875,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":876,"totalCitation":19,"totalCitationByYear":877,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":878,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":880,"pages":882},{"VOID":881},"18",{"VOID":883},"1-13","2020-09-10",2020,{"id":887,"createTime":888,"updateTime":889,"relativeEntities":890,"slug":891,"properties":892,"entityType":118,"verifyStatus":119,"verifyTime":889,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":901,"fullTextUrl":18,"authors":902,"publicationType":153,"publisherRelationship":1039,"citationCount":18,"citationInfo":18,"publishDate":1071,"publishYear":339,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"019fa077-4eed-444f-8b50-715e55fdc71b","2024-02-13T12:17:54.974+00:00","2024-12-18T23:38:43.031+00:00",[],"Health-economic-evidence-for-adjuvant-chemotherapy-in-stage-II-and-III-colon-cancer-a-systematic-review",{"references":893,"abstract":895,"title":897,"doi":899},{"VOID":894},"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–88.\nAraghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144(12):2992–3000.\nArnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.\nJongeneel G, Greuter MJE, van Erning FN, Koopman M, Vink GR, Punt CJA, et al. Model-based evaluation of the cost effectiveness of 3 versus 6 months’ adjuvant chemotherapy in high-risk stage II colon cancer patients. Therap Adv Gastroenterol. 2020;13:1756284820954114.\nTo YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, et al. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics. 2021;39(8):953–64.\nHanna CR, Robles-Zurita JA, Briggs A, Harkin A, Kelly C, McQueen J, et al. Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clin Colorectal Cancer. 2021;20(3):236–44.\nTie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.\nTie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710–7.\nClark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, Nguyen A, et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics. 2007;8:279.\nGray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.\nPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.\nProspero. A systematic review of health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer https:\u002F\u002Fwww.crd.york.ac.uk\u002Fprospero\u002Fdisplay_record.php?RecordID=265063: National Institute for Health Research; 2021\nGlynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv22–40.\nBenson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN Guidelines insights: rectal cancer, Version 6. 2020. J Natl Compr Canc Netw. 2020;18(7):806–15.\nArgilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2020. Ann Oncol. 2020;31(10):1291–305.\nBenson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehen Cancer Netw. 2021;19(3):329–59.\nHusereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ Br Med J. 2013;346: f1049.\nAyvaci MU, Shi J, Alagoz O, Lubner SJ. Cost-effectiveness of adjuvant FOLFOX and 5FU\u002FLV chemotherapy for patients with stage II colon cancer. Med Decis Making. 2013;33(4):521–32.\nSmith RD, Hall J, Gurney H, Harnett PR. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes’ C colonic carcinoma. Med J Aust. 1993;158(5):319–22.\nBrown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. JNCI J Nat Cancer Inst. 1994;86(6):424–30.\nLairson DR, Parikh RC, Cormier JN, Chan W, Du XL. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014;32(10):1005–13.\nNorum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 1997;8(1):65–70.\nMichel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, et al. Postoperative management of stage II\u002FIII colon cancer: a decision analysis. Gastroenterology. 1999;117(4):784–93.\nCassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU\u002FLV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer. 2006;94(8):1122–9.\nEggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006;95(9):1195–201.\nHo MY, Chang AY, Ruan JY, Cheung WY. Population-based cost-minimization analysis of CAPOX versus modified FOLFOX6 in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer. 2016;15(2):158–63.\nDouillard JY, Tilleul P, Ychou M, Dufour P, Perrocheau G, Seitz JF, et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology. 2007;72(3–4):248–54.\nDi Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, et al. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes’ C colon cancer: economic evaluation in an Italian NHS setting. Clin Drug Investig. 2008;28(10):645–55.\nGoerner M, Riemer-Hommel P. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer. Onkologie. 2009;32(11):647–52.\nShiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil\u002Fl-leucovorin for the adjuvant treatment of colon cancer in Japan. Pharmacoeconomics. 2009;27(7):597–608.\nHsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, et al. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil\u002Fleucovorin as adjuvant therapy for stage III colon cancer in Taiwan. Value Health. 2011;14(5):647–51.\nXie Q, Wen F, Wei YQ, Deng HX, Li Q. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer. Colorectal Dis. 2013;15(8):958–62.\nSoni A, Aspinall SL, Zhao X, Good CB, Cunningham FE, Chatta G, et al. Cost-effectiveness analysis of adjuvant stage III colon cancer treatment at veterans affairs medical centers. Oncol Res. 2014;22(5–6):311–9.\nChen HH, Chen WT, Lee HC, Lin JK, Fang CY, Chou YH, et al. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil\u002Fleucovorin in stage III colorectal cancer patients. Qual Life Res. 2015;24(2):473–84.\nLerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, Chindavijak S, Khuhaprema T, Tantai N, et al. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):687–700.\nLin JK, Tan EC, Yang MC. Comparing the effectiveness of capecitabine versus 5-fluorouracil\u002Fleucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool. Health Qual Life Outcomes. 2015;13:61.\nvan Gils CW, de Groot S, Tan SS, Redekop WK, Koopman M, Punt CJ, et al. Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl). 2015;24(3):321–32.\nMurad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Williston Park). 1997;11(9 Suppl 10):128–35.\nManiadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin. 2009;25(3):797–805.\nWen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, et al. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol. 2014;20(47):17976–84.\nHsu TC, Wang CC. Cost minimization comparison of oral UFT\u002Fleucovorin versus 5-fluorouracil\u002Fleucovorin as adjuvant therapy for colorectal cancer in Taiwan. J Comp Eff Res. 2019;8(2):73–9.\nPandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess. 2006;10(41):iii–iv (xi–xiv, 1–185).\nAballéa S, Boler A, Craig A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer. 2007;43(11):1687–93.\nAballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil\u002Fleucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.\nAttard CL, Maroun JA, Alloul K, Grima DT, Bernard LM. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol. 2010;17(1):17–24.\nShiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. Value Health. 2012;15(2):255–60.\nRobles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, et al. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. Br J Cancer. 2018;119(11):1332–8.\nIveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, et al. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technol Assess. 2019;23(64):1–88.\nHornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health. 2012;15(8):1014–21.\nAlberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, et al. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014;32(12):1231–43.\nJongeneel G, Greuter MJE, van Erning FN, Koopman M, Vink GR, Punt CJA, et al. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Therap Adv Gastroenterol. 2021;14:1756284821995715.\nAlarid-Escudero F, Schrag D, Kuntz KM. CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: an exploratory cost-effectiveness analysis. Value Health. 2021.\nRamsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294–303.\nNess RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650–7.\nIveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562–78.\nAspinall SL, Good CB, Zhao X, Cunningham FE, Heron BB, Geraci M, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015;15(1):62.\nTwelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil\u002Ffolinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23(5):1190–7.\nEichler H-G, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506.\nAnkarfeldt MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH. A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol. 2017;9:41–51.\nFigueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395–407.\nEfficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356–63.\nLemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49(6):784–96.\nRenouf D, Kennecke H, Gill S. Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 2008;7(6):386–9.\nTie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–72.",{"EN":896},"The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colon cancer (CC) and identify gaps in the available evidence that might inform further research. A systematic review of published economic evaluations was undertaken. Four databases were searched and full-text publications in English were screened for inclusion. A narrative synthesis was performed to summarise the evidence. Thirty-eight studies were identified and stratified by cancer stage and AC strategy. The majority (89%) were full economic evaluations considering both health outcomes, usually measured as quality-adjusted life years (QALYs), and costs. AC was found to be cost-effective compared to no AC for both stage II and III CC. Oral and oxaliplatin-based AC was cost-effective for stage III. Three months of CAPOX was cost-effective compared to 6-month in high-risk stage II and stage III CC. Preliminary evidence suggests that biomarker approaches to AC selection in stage II can reduce costs and improve health outcomes. Notably, assessment of QALYs were predominantly reliant on a small number of non-contemporary health-utility studies. Only 32% of studies considered societal costs such as travel and time off work. Published economic evaluations consistently supported the use of AC in stage II and III colon cancer. Biomarker-driven approaches to patient selection have great potential to be cost-effective, but more robust clinical and economic evidence is warranted. Patient surveys embedded into clinical trials may address critical knowledge gaps regarding accurate assessment of QALYs and societal costs in the modern era.",{"EN":898},"Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review",{"VOID":900},"10.1186\u002Fs12962-023-00422-2","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-023-00422-2",[903,928,957,986,1020],{"id":904,"sortIndex":19,"researcher":18,"roles":905,"affiliations":906,"properties":925},"7a3bdc45-698f-4056-bf9a-22074294fd6f",[126],[907,915],{"id":18,"sortIndex":19,"affiliation":908,"properties":18},{"id":909,"createTime":910,"updateTime":910,"relativeEntities":911,"slug":18,"properties":912,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"39bba645-0d17-4f93-b5ef-18f705eda4bb","2024-02-13T12:17:55.035+00:00",[],{"title":913},{"VI":914},"Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia",{"id":916,"sortIndex":94,"affiliation":917,"properties":924},"3448c891-b8f0-4291-ba45-5d9b2080e3c9",{"id":918,"createTime":919,"updateTime":919,"relativeEntities":920,"slug":18,"properties":921,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"101502f2-7a5b-4388-89cd-83830af9ce1c","2024-01-29T15:07:08.135+00:00",[],{"title":922},{"VI":923},"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia",{},{"title":926},{"VI":927},"Yat Hang To",{"id":929,"sortIndex":257,"researcher":18,"roles":930,"affiliations":931,"properties":954},"2b55369b-be5a-4a4e-ab83-c7664bbcbd8c",[126],[932,942,949],{"id":933,"sortIndex":257,"affiliation":934,"properties":941},"9ef6636f-b8cb-4833-baa8-caa93b8103d3",{"id":935,"createTime":936,"updateTime":936,"relativeEntities":937,"slug":18,"properties":938,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2681b819-7ed2-4f78-b56e-5aa12d48095b","2024-02-13T12:17:55.022+00:00",[],{"title":939},{"VI":940},"Faculty of Medicine and Health Sciences, University of Melbourne, Melbourne, Australia",{},{"id":943,"sortIndex":94,"affiliation":944,"properties":948},"bce6a44f-3194-4342-bcdb-4a33be3025dd",{"id":918,"createTime":919,"updateTime":919,"relativeEntities":945,"slug":18,"properties":946,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":947},{"VI":923},{},{"id":18,"sortIndex":19,"affiliation":950,"properties":18},{"id":909,"createTime":910,"updateTime":910,"relativeEntities":951,"slug":18,"properties":952,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":953},{"VI":914},{"title":955},{"VI":956},"Jeanne Tie",{"id":958,"sortIndex":94,"researcher":18,"roles":959,"affiliations":960,"properties":983},"60967976-c7b4-4cf6-a763-033b66651aa3",[126],[961,966,976],{"id":18,"sortIndex":19,"affiliation":962,"properties":18},{"id":909,"createTime":910,"updateTime":910,"relativeEntities":963,"slug":18,"properties":964,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":965},{"VI":914},{"id":967,"sortIndex":94,"affiliation":968,"properties":975},"393c0f30-9d13-4ac7-bbfd-513e815a48d9",{"id":969,"createTime":970,"updateTime":970,"relativeEntities":971,"slug":18,"properties":972,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"9970a737-7724-4777-9359-a7d9d39ca556","2024-02-13T12:17:55.017+00:00",[],{"title":973},{"VI":974},"Department of Medical Oncology, Western Health, Melbourne, Australia",{},{"id":977,"sortIndex":257,"affiliation":978,"properties":982},"1656468c-6a8a-46b1-99ec-99dcdfeb196c",{"id":935,"createTime":936,"updateTime":936,"relativeEntities":979,"slug":18,"properties":980,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":981},{"VI":940},{},{"title":984},{"VI":985},"Peter Gibbs",{"id":987,"sortIndex":270,"researcher":18,"roles":988,"affiliations":989,"properties":1018},"ff5a018d-ca01-4eff-9c78-af9866e55ca5",[126],[990,1000,1008],{"id":991,"sortIndex":94,"affiliation":992,"properties":999},"9ee17695-70aa-4725-b5c7-8a8512cf99d1",{"id":993,"createTime":994,"updateTime":994,"relativeEntities":995,"slug":18,"properties":996,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"d52dd2b2-7590-49f4-ac20-4eea2520cd64","2024-02-13T12:17:55.089+00:00",[],{"title":997},{"VI":998},"Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia",{},{"id":18,"sortIndex":19,"affiliation":1001,"properties":18},{"id":1002,"createTime":1003,"updateTime":1003,"relativeEntities":1004,"slug":18,"properties":1005,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"ade463d0-31f8-4eff-b929-93dde538b3c6","2024-01-28T14:05:56.950+00:00",[],{"title":1006},{"VI":1007},"Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia",{"id":1009,"sortIndex":257,"affiliation":1010,"properties":1017},"c5845908-2ebd-4df4-b92a-e4f975738365",{"id":1011,"createTime":1012,"updateTime":1012,"relativeEntities":1013,"slug":18,"properties":1014,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"c43fef51-5aee-43d2-a023-a804739ab260","2023-12-06T22:48:23.811+00:00",[],{"title":1015},{"VI":1016},"Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia",{},{"title":1019},{"VI":232},{"id":1021,"sortIndex":209,"researcher":18,"roles":1022,"affiliations":1023,"properties":1036},"9b7d7b96-a67b-468c-af70-0d25b2ddacb8",[126],[1024,1029],{"id":18,"sortIndex":19,"affiliation":1025,"properties":18},{"id":1002,"createTime":1003,"updateTime":1003,"relativeEntities":1026,"slug":18,"properties":1027,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1028},{"VI":1007},{"id":1030,"sortIndex":94,"affiliation":1031,"properties":1035},"a9897bff-c601-4e4e-bd8a-c73d49a80c25",{"id":993,"createTime":994,"updateTime":994,"relativeEntities":1032,"slug":18,"properties":1033,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1034},{"VI":998},{},{"title":1037},{"VI":1038},"Koen Degeling",{"url":901,"publisher":1040,"properties":1067},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1041,"slug":10,"properties":1042,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1045,"manageAffiliations":1046,"indexDatabases":1047,"url":91,"thumbnailPath":18,"statistic":1062,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":1043,"title":1044},{"VOID":13},{"EN":15},[],[],[1048,1055],{"id":54,"indexDatabase":1049,"url":67,"indexYears":68,"academicFieldIds":1054,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":1050,"label":1051,"description":1052,"key":64,"publicationTags":1053,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":1056,"url":88,"indexYears":18,"academicFieldIds":1061,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":1057,"label":1058,"description":1059,"key":84,"publicationTags":1060,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":1063,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1064,"totalCitation":19,"totalCitationByYear":1065,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1066,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":1068,"pages":1069},{"VOID":335},{"VOID":1070},"1-12","2023-01-31",{"id":1073,"createTime":1074,"updateTime":1075,"relativeEntities":1076,"slug":1077,"properties":1078,"entityType":118,"verifyStatus":119,"verifyTime":1075,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1087,"fullTextUrl":18,"authors":1088,"publicationType":153,"publisherRelationship":1116,"citationCount":18,"citationInfo":18,"publishDate":1148,"publishYear":1149,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"26f8f530-806e-48ca-a04e-31e62bb2d2aa","2024-02-11T10:25:27.208+00:00","2025-01-22T23:35:13.783+00:00",[],"A-population-based-model-for-priority-setting-across-the-care-continuum-and-across-modalities",{"references":1079,"abstract":1081,"title":1083,"doi":1085},{"VOID":1080},"Mitton C, Donaldson C: Health care priority setting: principles, practice and challenges. Cost effectiveness and Resource Allocation 2004, 2: 3. 10.1186\u002F1478-7547-2-3\nCoast J, Donovan J, Frankel S: Priority setting: the health care debate. J Wiley & Sons, England; 1996.\nSegal L, Chen Y: Priority setting models in health – A critique of alternative models. CHPE Research Report 22 Faculty of Business and Economics, Monash University; 2001. [http:\u002F\u002Fwww.monash.edu.au\u002Fcentres\u002Fche\u002Fpubs\u002Frr22.pdf]\nHauck K, Smith P, Goddard M: The Economics of Priority Setting for Health Care. A Literature Review'. Health Nutrition and Population Discussion Paper, The World Bank, Washington; 2003.\nMitton C, Donaldson C: Tools of the trade: A comparative analysis of approaches to priority setting in healthcare. Health Care Management Science 2003, 16: 96–105.\nSegal L, Richardson J: Economic Framework for Allocative Efficiency in the Health Sector. Australian Economic Review 1994, 2nd quarter: 89–98.\nDrummond M, Sculpher M, O'Brien B, Stoddart G: Methods for the Economic Evaluation of Health Care programmes. 3rd edition. Oxford, Oxford University Press; 2005.\nDepartment of Health and Ageing: Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefit Advisory Committee including major submissions involving economic analyses. Commonwealth Department of Health and Ageing, Canberra; 2002.\nSegal L, Day S, Chapman A, Osborne R: How can we reduce disease burden from osteoarthritis? An evidenced based priority setting model. Medical Journal of Australia 2004,180(5):supplement S11-S17.\nSegal L, Dalton A, Richardson J: Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promotion International 1998,13(3):197–09. 10.1093\u002Fheapro\u002F13.3.197\nSegal L: Allocative Efficiency in Health: Development of a Priority setting model and application to Non-insulin dependent diabetes mellitus. Doctoral thesis, Monash University, Clayton; 2000.\nSegal L, Mortimer D, Dalziel K: Risk Factor Study. How to Reduce the Burden of Harm from Tobacco Smoking, poor Nutrition, physical Inactivity and Alcohol misuse: Cost-Utility Analysis of 29 Interventions. In Centre for Health Economics, Research Paper 2005\u002F1. Monash University; 2005. www.monash.edu.au\u002Fcentres\u002Fche\u002Fpubs\u002Frp1.pdf\nMortimer D, Segal L: Economic Evaluation of Interventions for problem drinking and alcohol dependence: cost per QALY estimates. Alcohol and Alcoholism 2005, 40: 549–555. 10.1093\u002Falcalc\u002Fagh192\nDixon J, Welch H: Priority Setting: Lessons from Oregon. The Lancet 1991, 337: 891–4. 10.1016\u002F0140-6736(91)90213-9\nMooney G, Gerard K, Donalson C, Farrer S: Priority setting in purchasing. In HERU (Health Economics Research Unit). Research paper, University of Aberdeen, Scotland; 1992.\nCohen D: Marginal Analysis in Practice: An alternative to Needs assessment for Contracting Health Care. British Medical Journal 1994, 309: 781–784.\nTwaddle S, Walker A: Program budgeting and marginal analysis application within programmes to assist purchasing in Greater Glasgow Health Board. Health Policy 1995, 33: 91–105. 10.1016\u002F0168-8510(95)93671-M\nHutubessy R, Chisholm D, Edejer TT, WHO-CHOICE: Generalised cost-effectiveness analysis for national -level priority setting in the health sector. Cost Effectiveness and Resource Allocation 2003, 1: 8. 10.1186\u002F1478-7547-1-8\nMurray CJ, Evans DB, Acharya A, Baltussen RM: Development of WHO Guidelines on generalised cost-effectiveness analysis. Health Economics 2000, 9: 235–251. 10.1002\u002F(SICI)1099-1050(200004)9:3\u003C235::AID-HEC502>3.0.CO;2-O\nDrummond M, Torrance G, Mason J: Cost-effectiveness League Tables: More Harm than Good. Social Science and Medicine 1993,37(1):33–40. 10.1016\u002F0277-9536(93)90315-U\nPeacock S, Richardson J, Carter R: Setting Priorities in South Australian Community Health II: Marginal analysis in mental health services. In CHPE Research Report 22. Faculty of Business and Economics, Monash University; 1999. www.monash.edu.au\u002Fcentres\u002Fche\u002Fpubs\u002Frr14.pdf\nKumaranayake L, Walker D: Cost-effectiveness analysis and priority setting: Global approach without local meaning? In Health policy in a globalising world. Edited by: Lee K, Buse K, Fustukian S. Cambridge, Cambridge University Press; 2002:140–156.\nPaalman M, Bekedam H, Hawken L, Nyheim D: A critical review of priority setting in the health sector: the methodology of the 1993 World Development Report. Health Policy Plan 1998, 13: 13–31. 10.1093\u002Fheapol\u002F13.1.13\nCarter R, Stone C, Vos T, Hocking J, Mihalopolous C, Peacock S, Crowley S: Trial of program budgeting and marginal analysis (PBMA) to Assist Cancer Control Planning in Australia. Full Report. Centre for Health Program Evaluation, Monash University and University of Melbourne, Research Report 19; 2000.\nHaby M, Carter R, Mihalopolous C, Magnus A, Andrews G, Vos T: 'Assessing Cost-effectiveness – Mental Health: introduction to the study and methods'. Australian and New Zealand Journal of Psychiatry 2004, 38: 569–578. 10.1111\u002Fj.1440-1614.2004.01420.x\nMitton C, Donaldson C: Twenty-five years of program budgeting and marginal analysis in the health sector, 1974–1999. Journal of Health Services Research and Policy 2001, 6: 239–248. 10.1258\u002F1355819011927558\nMitton C, Donaldson C, Waldner H, Eagle C: The evolution of PBMA: Towards a macro-level priority setting framework for health regions. Health Care Management Science 2003, 6: 263–269. 10.1023\u002FA:1026285809115",{"EN":1082},"The Health-sector Wide (HsW) priority setting model is designed to shift the focus of priority setting away from 'program budgets' – that are typically defined by modality or disease-stage – and towards well-defined target populations with a particular disease\u002Fhealth problem. The key features of the HsW model are i) a disease\u002Fhealth problem framework, ii) a sequential approach to covering the entire health sector, iii) comprehensiveness of scope in identifying intervention options and iv) the use of objective evidence. The HsW model redefines the unit of analysis over which priorities are set to include all mutually exclusive and complementary interventions for the prevention and treatment of each disease\u002Fhealth problem under consideration. The HsW model is therefore incompatible with the fragmented approach to priority setting across multiple program budgets that currently characterises allocation in many health systems. The HsW model employs standard cost-utility analyses and decision-rules with the aim of maximising QALYs contingent upon the global budget constraint for the set of diseases\u002Fhealth problems under consideration. It is recognised that the objective function may include non-health arguments that would imply a departure from simple QALY maximisation and that political constraints frequently limit degrees of freedom. In addressing these broader considerations, the HsW model can be modified to maximise value-weighted QALYs contingent upon the global budget constraint and any political constraints bearing upon allocation decisions. The HsW model has been applied in several contexts, recently to osteoarthritis, that has demonstrated both its practical application and its capacity to derive clear evidenced-based policy recommendations. Comparisons with other approaches to priority setting, such as Programme Budgeting and Marginal Analysis (PBMA) and modality-based cost-effectiveness comparisons, as typified by Australia's Pharmaceutical Benefits Advisory Committee process for the listing of pharmaceuticals for government funding, demonstrate the value added by the HsW model notably in its greater likelihood of contributing to allocative efficiency.",{"EN":1084},"A population-based model for priority setting across the care continuum and across modalities",{"VOID":1086},"10.1186\u002F1478-7547-4-6","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002F1478-7547-4-6",[1089,1104],{"id":1090,"sortIndex":94,"researcher":18,"roles":1091,"affiliations":1092,"properties":1101},"14ba5c1d-e575-4450-8be3-c8d86cb841b8",[126],[1093],{"id":18,"sortIndex":19,"affiliation":1094,"properties":18},{"id":1095,"createTime":1096,"updateTime":1096,"relativeEntities":1097,"slug":18,"properties":1098,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"24f356c8-1e3e-4f34-b6c0-e7503a491df4","2023-12-17T19:01:25.533+00:00",[],{"title":1099},{"VI":1100},"Centre for Health Economics, Monash University, Melbourne, Australia",{"title":1102},{"VI":1103},"Duncan Mortimer",{"id":1105,"sortIndex":19,"researcher":18,"roles":1106,"affiliations":1107,"properties":1113},"2edea1eb-ccaf-4409-9a44-52f733a7a0cf",[126],[1108],{"id":18,"sortIndex":19,"affiliation":1109,"properties":18},{"id":1095,"createTime":1096,"updateTime":1096,"relativeEntities":1110,"slug":18,"properties":1111,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1112},{"VI":1100},{"title":1114},{"VI":1115},"Leonie Segal",{"url":1087,"publisher":1117,"properties":1144},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1118,"slug":10,"properties":1119,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1122,"manageAffiliations":1123,"indexDatabases":1124,"url":91,"thumbnailPath":18,"statistic":1139,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":1120,"title":1121},{"VOID":13},{"EN":15},[],[],[1125,1132],{"id":54,"indexDatabase":1126,"url":67,"indexYears":68,"academicFieldIds":1131,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":1127,"label":1128,"description":1129,"key":64,"publicationTags":1130,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":1133,"url":88,"indexYears":18,"academicFieldIds":1138,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":1134,"label":1135,"description":1136,"key":84,"publicationTags":1137,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":1140,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1141,"totalCitation":19,"totalCitationByYear":1142,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1143,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":1145,"pages":1147},{"VOID":1146},"4",{"VOID":337},"2006-03-28",2006,{"id":1151,"createTime":1152,"updateTime":1153,"relativeEntities":1154,"slug":1155,"properties":1156,"entityType":118,"verifyStatus":119,"verifyTime":1153,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":94,"primaryUrl":1165,"fullTextUrl":18,"authors":1166,"publicationType":153,"publisherRelationship":1276,"citationCount":18,"citationInfo":18,"publishDate":1307,"publishYear":339,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"d020ca3a-ed4e-4d51-849a-dc30234ae599","2024-01-25T12:10:37.307+00:00","2024-12-07T23:33:19.522+00:00",[],"Health-and-economic-outcomes-of-a-universal-early-intervention-for-parents-and-children-from-birth-to-age-five-evaluation-of-the-Salut-Programme-using-a-natural-experiment",{"references":1157,"abstract":1159,"title":1161,"doi":1163},{"VOID":1158},"Currie J, Rossin-Slater M. Early-life origins of life-cycle well-being: research and policy implications. J policy Anal Manag [the J Assoc Public Policy Anal Manag. 2015;34:208–42.\nGluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. Sci United States. 2004;305:1733–6.\nBen-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int. J. Epidemiol. England; 2002. p. 285–93.\nShonkoff JP, Boyce WT, McEwen BS. Neuroscience, molecular biology, and the childhood roots of health disparities: building a new framework for health promotion and disease prevention. JAMA United States. 2009;301:2252–9.\nKaroly AL, Kilburn MR, Cannon SJ. Early childhood interventions: “Proven results, future promise. Quad ACP. 2011;18:97.\nAos S, Lieb R, Mayfield J, Miller M, Pennucci A. Benefits and Costs of Prevention and Early Intervention Programs for Youth | Office of Justice Programs [Internet]. Available from: https:\u002F\u002Fwww.ojp.gov\u002Fncjrs\u002Fvirtual-library\u002Fabstracts\u002Fbenefits-and-costs-prevention-and-early-intervention-programs-youth.\nCannon JS, Kilburn MR, Karoly LA, Mattox T, Muchow AN, Buenaventura M. Investing Early: Taking Stock of Outcomes and Economic Returns from Early Childhood Programs. Rand Heal Q [Internet]. 2018;7:6. Available from: https:\u002F\u002Feuropepmc.org\u002Farticles\u002FPMC6075808.\nKaroly LA, Bigelow JH. The Economics of Investing in Universal Preschool Education in California. Econ Invest Univers Presch Educ Calif [Internet]. RAND Corporation; 2005 [cited 2021 Dec 9]; Available from: https:\u002F\u002Fwww.rand.org\u002Fpubs\u002Fmonographs\u002FMG349.html.\nReynolds AJ, Temple JA. Cost-effective early childhood development programs from preschool to third grade. Annu Rev Clin Psychol United States. 2008;4:109–39.\nKaroly L. The economic returns to early Childhood Education. Futur Child. 2016;26:37–55.\nNores M, Barnett WS. Benefits of early childhood interventions across the world: (Under) Investing in the very young. Econ Educ Rev [Internet]. 2010;29:271–82. Available from: https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS027277570900106X.\nDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of Health Care Programmes. Fourth edi. Oxford: Oxford University Press; 2015.\nCorbacho B, Bell K, Stamuli E, Richardson G, Ronaldson S, Hood K, et al. Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: evidence from the building blocks trial. J Eval Clin Pract England. 2017;23:1367–74.\nBell K, Corbacho B, Ronaldson S, Richardson G, Torgerson D, Robling M et al. The impact of pre and perinatal lifestyle factors on child long term health and social outcomes: a systematic review. Health Econ Rev [Internet]. 2018;8:2. Available from: https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13561-018-0186-6.\nWaitzman NJ, Jalali A, Grosse SD. Preterm birth lifetime costs in the United States in 2016: an update. Semin Perinatol United States. 2021;45:151390.\nEdvardsson K, Garvare R, Ivarsson A, Eurenius E, Mogren I, Nyström ME. Sustainable practice change: Professionals’ experiences with a multisectoral child health promotion programme in Sweden. BMC Health Serv Res [Internet]. 2011;11:61. Available from: https:\u002F\u002Fdoi.org\u002F10.1186\u002F1472-6963-11-61.\nElisabeth Nyström M, Höög E, Garvare R, Weinehall L, Ivarsson A. Change and learning strategies in large scale change programs. J Organ Chang Manag [Internet]. Emerald Group Publishing Limited; 2013;26:1020–44. Available from: https:\u002F\u002Fdoi.org\u002F10.1108\u002FJOCM-08-2012-0132.\nHaggstrom J, Sampaio F, Eurenius E, Pulkki-Brannstrom AM, Ivarsson A, Lindkvist M et al. Is the Salut Programme an effective and cost-effective universal health promotion intervention for parents and their children? A register-based retrospective observational study. BMJ Open [Internet]. 2017\u002F09\u002F25. 2017;7:e016732. Available from: https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fpubmed\u002F28939578.\nFeldman I, Eurenius E, Häggström J, Sampaio F, Lindkvist M, Pulkki-Brännström A-M et al. Effectiveness and cost-effectiveness of the Salut Programme: A universal health promotion intervention for parents and children - Protocol of a register-based retrospective observational study. BMJ Open. 2016;6.\nSwedish Association of Local Authorities and Regions (SALAR). [Sveriges kommuner och Regioner (SKR)]. Cost per patient database [Kostnad per patient, KPP] [Internet]. [cited 2021 Oct 11]. Available from: https:\u002F\u002Fskr.se\u002Fekonomijuridikstatistik\u002Fstatistik\u002Fkostnadperpatientkpp.1076.html.\nStatistics Sweden [Statistiska centralbyrån]. Consumer Price Index (CPI) [Konsumentprisindex (KPI)] [Internet]. Available from: https:\u002F\u002Fwww.scb.se\u002Fhitta-statistik\u002Fstatistik-efter-amne\u002Fpriser-och-konsumtion\u002Fkonsumentprisindex\u002Fkonsumentprisindex-kpi\u002Fpong\u002Ftabell-och-diagram\u002Fkonsumentprisindex-kpi\u002Fkpi-faststallda-tal-1980100\u002F.\nCCEMG - EPPI-Centre. Cost Converter v.1.4: web-based tool for adjusting estimates of cost using IMF source dataset for PPP [Internet]. [cited 2021 Jun 3]. Available from: https:\u002F\u002Feppi.ioe.ac.uk\u002Fcostconversion\u002Fdefault.aspx.\nAbadie A, Imbens GW. Large Sample Properties of Matching Estimators for Average Treatment Effects. Econometrica [Internet]. 2006;74:235–67. Available from: https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002F10.1111\u002Fj.1468-0262.2006.00655.x.\nAbadie A, Imbens GW. On the Failure of the Bootstrap for Matching Estimators. Econometrica [Internet]. 2008;76:1537–57. Available from: https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002F10.3982\u002FECTA6474.\nHartfiel N, Edwards R. Cost–consequence analysis of public health interventions. 2019. p. 233–47.\nHenderson J, Carson C, Redshaw M. Impact of preterm birth on maternal well-being and women’s perceptions of their baby: a population-based survey. BMJ Open [Internet]. 2016;6:e012676. Available from: https:\u002F\u002Fbmjopen.bmj.com\u002Fcontent\u002F6\u002F10\u002Fe012676.abstract\nGutbrod T, Wolke D, Soehne B, Ohrt B, Riegel K. Effects of gestation and birth weight on the growth and development of very low birthweight small for gestational age infants: a matched group comparison. Arch Dis Child - Fetal Neonatal Ed [Internet]. 2000;82:F208 LP-F214. Available from: http:\u002F\u002Ffn.bmj.com\u002Fcontent\u002F82\u002F3\u002FF208.abstract.\nRosholm M, Paul A, Bleses D, Højen A, Dale S, Jensen P, ARE IMPACTS OF EARLY INTERVENTIONS IN THE SCANDINAVIAN WELFARE STATE CONSISTENT WITH A HECKMAN CURVE? A META-ANALYSIS. P,. J Econ Surv [Internet]. 2021;35:106–40. Available from: https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002Fhttps:\u002F\u002Fdoi.org\u002F10.1111\u002Fjoes.12400.\nBeckmann K, Garmo H, Franck Lissbrant I, Stattin P. The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. Cancers (Basel). 2021;13.\nBaba S, Wikström A-K, Stephansson O, Cnattingius S. Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. BJOG An Int J Obstet Gynaecol [Internet]. 2013;120:456–62. Available from: https:\u002F\u002Fobgyn.onlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002Fhttps:\u002F\u002Fdoi.org\u002F10.1111\u002F1471-0528.12067.\nWikström A-K, Cnattingius S, Galanti MR, Kieler H, Stephansson O. Effect of Swedish snuff (snus) on preterm birth. BJOG An Int J Obstet Gynaecol [Internet]. 2010;117:1005–10. Available from: https:\u002F\u002Fobgyn.onlinelibrary.wiley.com\u002Fdoi\u002Fabs\u002F10.1111\u002Fj.1471-0528.2010.02575.x.\nNutbeam D. Evaluating Health Promotion—Progress, Problems and solutions. Health Promot Int [Internet]. 1998;13:27–44. Available from: https:\u002F\u002Fdoi.org\u002F10.1093\u002Fheapro\u002F13.1.27.",{"EN":1160},"The aim of this study was to investigate the health and economic outcomes of a universal early intervention for parents and children, the Salut Programme, from birth to when the child completed five years of age. This study adopted a retrospective observational design using routinely collected linked register data with respect to both exposures and outcomes from Västerbotten county, in northern Sweden. Making use of a natural experiment, areas that received care-as-usual (non-Salut area) were compared to areas where the Programme was implemented after 2006 (Salut area) in terms of: (i) health outcomes, healthcare resource use and costs around pregnancy, delivery and birth, and (ii) healthcare resource use and related costs, as well as costs of care of sick child. We estimated total cumulative costs related to inpatient and specialised outpatient care for mothers and children, and financial benefits paid to mothers to stay home from work to care for a sick child. Two analyses were conducted: a matched difference-in difference analysis using the total sample and an analysis including a longitudinal subsample. The longitudinal analysis on mothers who gave birth in both pre- and post-measure periods showed that mothers exposed to the Programme had on average 6% (95% CI 3–9%) more full-term pregnancies and 2% (95% CI 0.03-3%) more babies with a birth weight ≥ 2500 g, compared to mothers who had care-as-usual. Savings were incurred in terms of outpatient care costs for children of mothers in the Salut area ($826). The difference-in-difference analysis using the total sample did not result in any significant differences in health outcomes or cumulative resource use over time. The Salut Programme achieved health gains, as a health promotion early intervention for children and parents, in terms of more full-term pregnancies and more babies with a birth weight ≥ 2500 g, at reasonable cost, and may lead to lower usage of outpatient care. Other indicators point towards positive effects, but the small sample size may have led to underestimation of true differences.",{"EN":1162},"Health and economic outcomes of a universal early intervention for parents and children from birth to age five: evaluation of the Salut Programme using a natural experiment",{"VOID":1164},"10.1186\u002Fs12962-023-00439-7","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-023-00439-7",[1167,1184,1211,1228,1240,1252,1264],{"id":1168,"sortIndex":94,"researcher":18,"roles":1169,"affiliations":1170,"properties":1181},"fbc03cf6-3489-4d39-a17a-88d9cf0e64d9",[126],[1171],{"id":18,"sortIndex":19,"affiliation":1172,"properties":18},{"id":1173,"createTime":1174,"updateTime":1175,"relativeEntities":1176,"slug":1177,"properties":1178,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f00c6e90-5107-4b2b-a876-c7fad905e9d9","2024-01-12T14:10:21.168+00:00","2024-10-16T10:28:51.370+00:00",[],"Department-of-Statistics-Ume%C3%A5-School-of-Business-and-Economics-Ume%C3%A5-University-Ume%C3%A5-Sweden",{"title":1179},{"VI":1180},"Department of Statistics, Umeå School of Business and Economics, Umeå University, Umeå, Sweden",{"title":1182},{"VI":1183},"Jenny Häggström",{"id":1185,"sortIndex":257,"researcher":18,"roles":1186,"affiliations":1187,"properties":1208},"c674f553-0b87-478b-aff6-fc61a7895d7b",[126],[1188,1198],{"id":18,"sortIndex":19,"affiliation":1189,"properties":18},{"id":1190,"createTime":1191,"updateTime":1192,"relativeEntities":1193,"slug":1194,"properties":1195,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"1837c0b0-725d-4db1-a45c-a992ad90e569","2024-02-06T05:47:39.600+00:00","2024-12-06T04:03:52.161+00:00",[],"Department-of-Public-Health-and-Caring-Sciences-Uppsala-University-Uppsala-Sweden",{"title":1196},{"VI":1197},"Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden",{"id":1199,"sortIndex":94,"affiliation":1200,"properties":1207},"58964d61-fc61-4324-b0f7-046c0faf18a8",{"id":1201,"createTime":1202,"updateTime":1202,"relativeEntities":1203,"slug":18,"properties":1204,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"426ad486-77fa-45c2-8ffb-84632d9cbd93","2024-01-25T12:10:37.374+00:00",[],{"title":1205},{"VI":1206},"Department of Medical Sciences, Respiratory-, Allergy- and Sleep Medicine Research Unit, Uppsala University, Uppsala, Sweden",{},{"title":1209},{"VI":1210},"Richard Ssegonja",{"id":1212,"sortIndex":270,"researcher":18,"roles":1213,"affiliations":1214,"properties":1225},"3cdc491d-47f8-4c0e-97cd-9f96646e20b9",[126],[1215],{"id":18,"sortIndex":19,"affiliation":1216,"properties":18},{"id":1217,"createTime":1218,"updateTime":1219,"relativeEntities":1220,"slug":1221,"properties":1222,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b3f821ff-fdb8-434a-843a-6bf81630dd3f","2024-01-13T13:31:22.049+00:00","2024-09-26T21:35:51.019+00:00",[],"Department-of-Epidemiology-and-Global-Health-Ume%C3%A5-University-Ume%C3%A5-Sweden",{"title":1223},{"VI":1224},"Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden",{"title":1226},{"VI":1227},"Eva Eurenius",{"id":1229,"sortIndex":792,"researcher":18,"roles":1230,"affiliations":1231,"properties":1237},"58003948-9f13-4ac2-a696-f4b441332b5d",[126],[1232],{"id":18,"sortIndex":19,"affiliation":1233,"properties":18},{"id":1190,"createTime":1191,"updateTime":1192,"relativeEntities":1234,"slug":1194,"properties":1235,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1236},{"VI":1197},{"title":1238},{"VI":1239},"Inna Feldman",{"id":1241,"sortIndex":19,"researcher":18,"roles":1242,"affiliations":1243,"properties":1249},"1009c8a5-c6fb-4529-97c0-6c29324c2c94",[126],[1244],{"id":18,"sortIndex":19,"affiliation":1245,"properties":18},{"id":1190,"createTime":1191,"updateTime":1192,"relativeEntities":1246,"slug":1194,"properties":1247,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1248},{"VI":1197},{"title":1250},{"VI":1251},"Filipa Sampaio",{"id":1253,"sortIndex":594,"researcher":18,"roles":1254,"affiliations":1255,"properties":1261},"a425b19f-daf6-4e75-ae3d-9d6b240b8fee",[126],[1256],{"id":18,"sortIndex":19,"affiliation":1257,"properties":18},{"id":1217,"createTime":1218,"updateTime":1219,"relativeEntities":1258,"slug":1221,"properties":1259,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1260},{"VI":1224},{"title":1262},{"VI":1263},"Anni-Maria Pulkki-Brännström",{"id":1265,"sortIndex":209,"researcher":18,"roles":1266,"affiliations":1267,"properties":1273},"a117e843-eb63-4cb0-b444-7fd0545845cc",[126],[1268],{"id":18,"sortIndex":19,"affiliation":1269,"properties":18},{"id":1217,"createTime":1218,"updateTime":1219,"relativeEntities":1270,"slug":1221,"properties":1271,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1272},{"VI":1224},{"title":1274},{"VI":1275},"Anneli Ivarsson",{"url":1165,"publisher":1277,"properties":1304},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1278,"slug":10,"properties":1279,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1282,"manageAffiliations":1283,"indexDatabases":1284,"url":91,"thumbnailPath":18,"statistic":1299,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":1280,"title":1281},{"VOID":13},{"EN":15},[],[],[1285,1292],{"id":54,"indexDatabase":1286,"url":67,"indexYears":68,"academicFieldIds":1291,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":1287,"label":1288,"description":1289,"key":64,"publicationTags":1290,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":1293,"url":88,"indexYears":18,"academicFieldIds":1298,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":1294,"label":1295,"description":1296,"key":84,"publicationTags":1297,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":1300,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1301,"totalCitation":19,"totalCitationByYear":1302,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1303,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":1305,"pages":1306},{"VOID":335},{"VOID":1070},"2023-05-04",{"id":1309,"createTime":1310,"updateTime":1311,"relativeEntities":1312,"slug":1313,"properties":1314,"entityType":118,"verifyStatus":119,"verifyTime":1311,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1323,"fullTextUrl":18,"authors":1324,"publicationType":153,"publisherRelationship":1428,"citationCount":18,"citationInfo":18,"publishDate":1460,"publishYear":885,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"e5388d9e-086a-485e-88c3-6f235267444f","2024-01-01T06:57:46.897+00:00","2024-12-14T23:31:28.423+00:00",[],"Factors-affecting-the-technical-efficiency-of-rural-primary-health-care-centers-in-Hamadan-Iran-data-envelopment-analysis-and-Tobit-regression",{"references":1315,"abstract":1317,"title":1319,"doi":1321},{"VOID":1316},"Hadipour H, Kavoosi-Kalashami M, Salari A, Motamed MK. How efficient rural healthcare centres work in Iran? Int J Collab Res Intern Med Public Health. 2018;10(1):747–59.\nRashidian A, Jahanmehr N, Pourreza A, Majdzadeh S, Goudarzi R. Evaluating performance of medical universities in Iran during 2002 to 2007: a technical efficiency study. Hakim Res J. 2010;13(1):58–68.\nKeehan SP, Stone DA, Poisal JA, Cuckler GA, Sisko AM, Smith SD, et al. National health expenditure projections, 2016–25: price increases, aging push sector to 20 percent of economy. Health Aff. 2017;36(3):553–63.\nAryankhesal A, Etemadi M, Mohseni M, Azami-Aghdash S, Nakhaei M. Catastrophic health expenditure in Iran: a review article. Iran J Public Health. 2018;47(2):166.\nde Mast J, Kemper B, Does RJ, Mandjes M, van der Bijl Y. Process improvement in healthcare: overall resource efficiency. Qual Reliab Eng Int. 2011;27(8):1095–106.\nHsu J. The relative efficiency of public and private service delivery. World Health Rep Backgr Pap. 2010;39:1–9.\nZare Ahmadabadi H, Masoudian S, Banadkouki Z, Reza M. Evaluating the technical efficiency of Yazd City health centers with a combined approach of DEA and GT. SSU_Journals. 2019;26(8):717–32.\nOglobin C. Health care efficiency across countries: a stochastic frontier analysis. Appl Econom Int Dev. 2011;11(1):5–14.\nZhang Y, Wang Q, Jiang T, Wang J. Equity and efficiency of primary health care resource allocation in mainland China. Int J Equity Health. 2018;17(1):140.\nWorld Health Organization. Declaration of Alma Ata. Geneva: World Health Organization; 1978. p. 2008.\nTavassoli M. Iranian health houses open the door to primary care. Bull World Health Organ. 2008;86(8):585–6.\nTakian A, Doshmangir L, Rashidian A. Implementing family physician programme in rural Iran: exploring the role of an existing primary health care network. Fam Pract. 2013;30(5):551–9.\nCouper I. Rural primary health care in Iran. S Afr Fam Pract. 2004;46(5):37–9.\nKiadaliri AA, Najafi B, Haghparast-Bidgoli H. Geographic distribution of need and access to health care in rural population: an ecological study in Iran. Int J Equity Health. 2011;10(1):39.\nRahmany K, Barati M, Ferdosi M, Rakhshan A, Nemati A. Strategies for reducing expenditures in Iran’s health transformation plan: a qualitative study. Med J Islam Repub Iran. 2018;32:102.\nKirigia JM, Sambo LG, Renner A, Alemu W, Seasa S, Bah Y. Technical efficiency of primary health units in Kailahun and Kenema districts of Sierra Leone. Int Arch Med. 2011;4(1):15.\nRostami Golmohammadi F, Kazemi Karyani A, Goudarzian M, Asefzadeh S, Mehraban S. Efficiency determination of rural health centers of Ghazvin Province using data envelopment analysis approach in 2006–2010 period. J Sabzevar Univ Med Sci. 2016;23(3):444–57. https:\u002F\u002Fdoi.org\u002F10.21859\u002Fsums-2303444.\nTabrizi JS, Pourasghar F, Nikjoo RG. Status of Iran’s primary health care system in terms of health systems control knobs: a review article. Iran J Public Health. 2017;46(9):1156.\nMilliken O, Devlin RA, Barham V, Hogg W, Dahrouge S, Russell G. Comparative efficiency assessment of primary care service delivery models using data envelopment analysis. Can Public Policy. 2011;37(1):85–109.\nZakowska I, Godycki-Cwirko M. Data envelopment analysis applications in primary health care: a systematic review. Fam Pract. 2019;37(2):147–53. https:\u002F\u002Fdoi.org\u002F10.1093\u002Ffampra\u002Fcmz057.\nMarschall P, Flessa S. Efficiency of primary care in rural Burkina Faso. A two-stage DEA analysis. Health Econ Rev. 2011;1(1):5.\nNovignon J, Nonvignon J. Improving primary health care facility performance in Ghana: efficiency analysis and fiscal space implications. BMC Health Serv Res. 2017;17(1):399.\nDeidda M, Lupiáñez-Villanueva F, Codagnone C, Maghiros I. Using data envelopment analysis to analyse the efficiency of primary care units. J Med Syst. 2014;38(10):122.\nAlhassan RK, Nketiah-Amponsah E, Akazili J, Spieker N, Arhinful DK, Rinke de Wit TF. Efficiency of private and public primary health facilities accredited by the National Health Insurance Authority in Ghana. Cost Eff Resour Alloc. 2015;13(1):23. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12962-015-0050-z.\nZhang T, Lu W, Tao H. Efficiency of health resource utilisation in primary-level maternal and child health hospitals in Shanxi Province, China: a bootstrapping data envelopment analysis and truncated regression approach. BMC Health Serv Res. 2020;20(1):1–9.\nSamut PK, Cafrı R. Analysis of the efficiency determinants of health systems in OECD countries by DEA and panel Tobit. Soc Indic Res. 2016;129(1):113–32.\nGuo H, Zhao Y, Niu T, Tsui K-L. Hong Kong hospital authority resource efficiency evaluation: via a novel DEA-Malmquist model and Tobit regression model. PLoS ONE. 2017;12(9):e0184211.\nKohl S, Schoenfelder J, Fügener A, Brunner JO. The use of data envelopment analysis (DEA) in healthcare with a focus on hospitals. Health Care Manag Sci. 2019;22(2):245–86.\nJamil N. A comparison of iterative methods for the solution of non-linear systems of equations. Int J Emerg Sci. 2013;3:119–30.\nBaltagi BH. Econometric analysis of panel data. 5th ed. New York: Wiley; 2013.\nNekoei-Moghadam M, Nazari J, Amiresmaili MR, Amini S. Factors affecting fee-setting for dental services in Iran’s private sector: dentists’ perspective. Shiraz E-Med J. 2019;20(3):e74247.\nTop M, Konca M, Sapaz B. Technical efficiency of healthcare systems in African countries: an application based on data envelopment analysis. Health Policy Technol. 2020;9(1):62–8.\nIbrahim MD, Daneshvar S, Hocaoğlu MB, Oluseye OWG. An estimation of the efficiency and productivity of healthcare systems in Sub-Saharan Africa: health-centred millennium development goal-based evidence. Soc Indic Res. 2019;143(1):371–89.\nOikonomou N, Tountas Y, Mariolis A, Souliotis K, Athanasakis K, Kyriopoulos J. Measuring the efficiency of the Greek rural primary health care using a restricted DEA model; the case of southern and western Greece. Health Care Manag Sci. 2016;19(4):313–25.\nAkazili J, Adjuik M, Chatio S, Kanyomse E, Hodgson A, Aikins M, et al. What are the technical and allocative efficiencies of public health centres in Ghana? Ghana Med J. 2008;42(4):149.\nKirirgia J, Sambo L, Scheel H. Technical efficiency of public clinics in Kwazulu-Natal province of South Africa. East Afr Med J. 2001;78(3):1–14.\nTajedini F, Delbarpoor Ahmadi S, Ehdaievand F, Moghimi Dehkordi B, Torkaman Nejad S, Farsar A. Epidemiological features of children mortality in the area covered by Shahid Beheshti university of medical sciences in 2012. J Clin Nurs Midwifery. 2014;3(1):62–71.\nMoeni SA, Tamjidzad Z. Child mortality rate and its causes in rural areas of Ardabil Province with emphasis on Pars Abad City. J Health. 2010;1(2):52–8.\nNaghibi SA, Moosazadeh M, Shojaee J. Epidemiological features of under 5 year children mortality in Mazandaran. J Health Res Community. 2015;1(1):11–9.\nShapiro D, Tenikue M. Women’s education, infant and child mortality, and fertility decline in urban and rural sub-Saharan Africa. Demogr Res. 2017;37:669–708.\nvan Poppel F, Reher D, Liefbroer A. The relationship between infant and child mortality and fertility in the Netherlands. Washington, D.C: National Academies Press; 2012.\nAlmasi-Hashiani A, Sepidarkish M, Vesali S, Omani SR. The correlation of human development index on fertility and mortality rate: a global ecological study. Int J Pediatr. 2016;4(12):4071–80.",{"EN":1318},"Studying and monitoring the efficiency of primary health care centers has a special place in the health system. Although studies have been conducted in the field of efficiency in Iran, few have focused on rural primary health care centers. In addition, previous studies have not used the child mortality rate and Behvarzes as input and output. The present study was conducted aimed to estimate the technical efficiency of rural primary health care centers and determinant factors in Hamadan using data envelopment analysis and Tobit regression. This is a Longitudinal study of rural primary health care centers in Hamadan province (2002–2016). Data Envelopment Analysis was employed to estimate technical efficiency of sampled health facilities while Panel Tobit Analysis was applied to predict factors associated with efficiency levels. The outputs were child mortality rate under 1 year of age and child mortality rate 1 year to 5 years of age. The input was Behvarzes (rural health workers). The results of efficiency analysis showed that the average efficiency scores of the centers had a fluctuating trend during the period of the study, but the average performance scores generally decreased in 2016, as compared with 2002. The highest and lowest average performance scores were observed in 2003 (0.78) and 2013 (0.56), respectively. Number of physicians and rural primary healthcare centers per population had a positive statistically significant and the number of midwives and the total fertility per population had a negative statistically significant effect on efficiency. The findings suggest some level of wastage of health resources in primary health centers. Findings indicate a level of waste of health resources in primary health centers. Behvarz functions in providing primary care services can be considered in the reallocation and optimal use of available resources at the level of rural health centers.",{"EN":1320},"Factors affecting the technical efficiency of rural primary health care centers in Hamadan, Iran: data envelopment analysis and Tobit regression",{"VOID":1322},"10.1186\u002Fs12962-020-00249-1","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12962-020-00249-1",[1325,1340,1352,1367,1379,1394,1411],{"id":1326,"sortIndex":257,"researcher":18,"roles":1327,"affiliations":1328,"properties":1337},"a7bbe7eb-6b62-4f99-8ed7-97f04052a9db",[126],[1329],{"id":18,"sortIndex":19,"affiliation":1330,"properties":18},{"id":1331,"createTime":1332,"updateTime":1332,"relativeEntities":1333,"slug":18,"properties":1334,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"8ed53aa6-785c-4162-8298-05d6b6202f2d","2024-01-01T06:57:47.027+00:00",[],{"title":1335},{"VI":1336},"Social Determinants of Health Research Center, Faculty of Health, Mashhad University of Medical Sciences, Mashhad, Iran",{"title":1338},{"VI":1339},"Ali Vafaee Najar",{"id":1341,"sortIndex":94,"researcher":18,"roles":1342,"affiliations":1343,"properties":1349},"43cd1564-2e3b-440e-b54f-2f38b7c75eef",[126],[1344],{"id":18,"sortIndex":19,"affiliation":1345,"properties":18},{"id":1331,"createTime":1332,"updateTime":1332,"relativeEntities":1346,"slug":18,"properties":1347,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1348},{"VI":1336},{"title":1350},{"VI":1351},"Javad Javan-Noughabi",{"id":1353,"sortIndex":792,"researcher":18,"roles":1354,"affiliations":1355,"properties":1364},"5c7de4ab-f9de-4cc2-b39e-6d8473a7167c",[126],[1356],{"id":18,"sortIndex":19,"affiliation":1357,"properties":18},{"id":1358,"createTime":1359,"updateTime":1359,"relativeEntities":1360,"slug":18,"properties":1361,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"93a776db-a1f2-427a-861b-0e079b983e45","2024-01-12T00:40:05.385+00:00",[],{"title":1362},{"VI":1363},"Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran",{"title":1365},{"VI":1366},"Reza Jahangiri",{"id":1368,"sortIndex":19,"researcher":18,"roles":1369,"affiliations":1370,"properties":1376},"1028a641-e5d3-4719-8cd3-2c32fd052156",[126],[1371],{"id":18,"sortIndex":19,"affiliation":1372,"properties":18},{"id":1358,"createTime":1359,"updateTime":1359,"relativeEntities":1373,"slug":18,"properties":1374,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1375},{"VI":1363},{"title":1377},{"VI":1378},"Saeed Mohammadpour",{"id":1380,"sortIndex":270,"researcher":18,"roles":1381,"affiliations":1382,"properties":1391},"fa57d31b-6172-4853-9b99-ff2818ad66d3",[126],[1383],{"id":18,"sortIndex":19,"affiliation":1384,"properties":18},{"id":1385,"createTime":1386,"updateTime":1386,"relativeEntities":1387,"slug":18,"properties":1388,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"5fc98340-61fe-4bc1-ba4d-1426b213a245","2024-01-01T06:57:47.054+00:00",[],{"title":1389},{"VI":1390},"Department of Health Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran",{"title":1392},{"VI":1393},"Moharram Zangeneh",{"id":1395,"sortIndex":209,"researcher":18,"roles":1396,"affiliations":1397,"properties":1408},"91410e19-2ef3-41f2-a46e-55bcee499435",[126],[1398],{"id":18,"sortIndex":19,"affiliation":1399,"properties":18},{"id":1400,"createTime":1401,"updateTime":1402,"relativeEntities":1403,"slug":1404,"properties":1405,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6e4f6bea-3ddb-4d32-b683-e74e0c6c4da6","2024-04-18T11:33:48.272+00:00","2024-11-26T17:04:40.887+00:00",[],"Mashhad-University-of-Medical-Sciences-Mashhad-Iran",{"title":1406},{"EN":1407},"Mashhad University of Medical Sciences, Mashhad, Iran",{"title":1409},{"VI":1410},"Shaghayegh Yousefi",{"id":1412,"sortIndex":594,"researcher":18,"roles":1413,"affiliations":1414,"properties":1425},"619fd590-ed08-49b5-a0af-c2801498fd32",[126],[1415],{"id":18,"sortIndex":19,"affiliation":1416,"properties":18},{"id":1417,"createTime":1418,"updateTime":1419,"relativeEntities":1420,"slug":1421,"properties":1422,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b72b0199-5095-492c-81f4-952e40aa2856","2024-04-17T19:47:04.726+00:00","2025-01-30T16:42:21.938+00:00",[],"Health-Equity-Research-Center-Tehran-University-of-Medical-Sciences-Tehran-Iran",{"title":1423},{"EN":1424},"Health Equity Research Center, Tehran University of Medical Sciences, Tehran, Iran",{"title":1426},{"VI":1427},"Mojtaba Nouhi",{"url":1323,"publisher":1429,"properties":1456},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1430,"slug":10,"properties":1431,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1434,"manageAffiliations":1435,"indexDatabases":1436,"url":91,"thumbnailPath":18,"statistic":1451,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":1432,"title":1433},{"VOID":13},{"EN":15},[],[],[1437,1444],{"id":54,"indexDatabase":1438,"url":67,"indexYears":68,"academicFieldIds":1443,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":1439,"label":1440,"description":1441,"key":64,"publicationTags":1442,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":1445,"url":88,"indexYears":18,"academicFieldIds":1450,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":1446,"label":1447,"description":1448,"key":84,"publicationTags":1449,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":1452,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1453,"totalCitation":19,"totalCitationByYear":1454,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1455,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":1457,"pages":1458},{"VOID":881},{"VOID":1459},"1-8","2020-11-23",{"id":1462,"createTime":1463,"updateTime":1464,"relativeEntities":1465,"slug":1466,"properties":1467,"entityType":118,"verifyStatus":119,"verifyTime":1464,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1476,"fullTextUrl":18,"authors":1477,"publicationType":153,"publisherRelationship":1522,"citationCount":18,"citationInfo":18,"publishDate":1554,"publishYear":1149,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":189},"f2ca4444-312d-4890-b494-1f52fb3d984d","2023-11-28T02:13:58.135+00:00","2025-02-25T23:26:38.659+00:00",[],"Cost-of-illness-of-hyponatremia-in-the-United-States",{"references":1468,"abstract":1470,"title":1472,"doi":1474},{"VOID":1469},"Schrier RW: The patient with hyponatremia or hypernatremia. In Manual of Nephrology. Philadelphia, Lippincott Williams & Wilkins; 2000:21–36.\nAdrogue HJ, Madias NE: Hyponatremia. N Engl J Med 2000, 342: 1581–1589. 10.1056\u002FNEJM200005253422107\nJanicic N, Verbalis JG: Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003, 32: 459–81, vii. 10.1016\u002FS0889-8529(03)00004-5\nDeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM: Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol 1990, 34: 163–166.\nKleinfeld M, Casimir M, Borra S: Hyponatremia as observed in a chronic disease facility. J Am Geriatr Soc 1979, 27: 156–161.\nMiller M, Morley JE, Rubenstein LZ: Hyponatremia in a nursing home population. J Am Geriatr Soc 1995, 43: 1410–1413.\nHawkins RC: Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003, 337: 169–172. 10.1016\u002Fj.cccn.2003.08.001\nLee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73: 257–267.\nPanciroli C, Galloni G, Oddone A, Marangoni E, Masa A, Cominesi WR, Caizzi V, Pezzi C, Belletti S, Cornalba C, Orlandi M: Prognostic value of hyponatremia in patients with severe chronic heart failure. Angiology 1990, 41: 631–638.\nChin MH, Goldman L: Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996, 156: 1814–1820. 10.1001\u002Farchinte.156.16.1814\nTerzian C, Frye EB, Piotrowski ZH: Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994, 9: 89–91.\nAnderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985, 102: 164–168.\nKrumholz HM, Chen YT, Bradford WD, Cerese J: Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care 1999, 5: 715–723.\nDrummond M: Cost-of-illness studies: a major headache? Pharmacoeconomics 1992, 2: 1–4.\nDrummond MF, O'Brien BJ, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. 2nd edition. Oxford, Oxford Medical Publications; 1997.\nFink A, Kosecoff J, Chassin M, Brook RH: Consensus methods: characteristics and guidelines for use. Am J Public Health 1984, 74: 979–983.\nSniezek JA: A comparison group of techniques for judgmental forecasting by groups with common information. Group Organization Stud 1990, 15: 5–19.\nMurray MI, Halpern MT, Leppik IE: Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996, 23: 139–148. 10.1016\u002F0920-1211(95)00090-9\nPlumb JM, Guest JF: Annual cost of erectile dysfunction to UK Society. Pharmacoeconomics 1999, 16: 699–709. 10.2165\u002F00019053-199916060-00008\nMazzuca SA, Cohen SJ: Scoring patient management problems: external validation of expert consensus. Eval Health Prof 1982, 5: 210–217.\nSanmarco ME, Brooks SH, Blankenhorn DH: Reproducibility of a consensus panel in the interpretation of coronary angiograms. Am Heart J 1978, 96: 430–437. 10.1016\u002F0002-8703(78)90151-5\nSeverens JL, Habraken JM, Duivenvoorden S, Frederiks CM: The cost of illness of pressure ulcers in The Netherlands. Adv Skin Wound Care 2002, 15: 72–77. 10.1097\u002F00129334-200203000-00008\nAgency for Healthcare Research and Quality (AHRQ): Healthcare Cost & Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) database [online]. [http:\u002F\u002Fwww.ahrq.gov]\nTierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ: The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1986, 1: 380–385.\nCenters for Medicare and Medicaid Services (CMS): Data on hospitals' cost-to-charge ratios [online]. [http:\u002F\u002Fcms.hhs.gov\u002Fproviders\u002Fpufdownload\u002Fdefault.asp]\nU.S. Bureau of Labor Statistics: Consumer price index [online]. [http:\u002F\u002Fwww.bls.gov\u002Fcpi.]\nMAG Mutual Healthcare Solutions Inc.: Physicians' fee and coding guide (a comprehensive fee & coding reference). Augusta (GA), HealthCare Consultants of America Inc.; 2004.\nCenters for Medicare and Medicaid Services (CMS): Data on Ambulatory Payment Classification System. [http:\u002F\u002Fcms.hhs.gov\u002Fpaymentsystems]\nParamore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004, 22: 275–284. 10.2165\u002F00019053-200422050-00001\nNational Institutes of Health (NIH): Information for disease and conditions. Appendix to: Disease-specific estimates of direct and indirect costs of illness and NIH support. , National Institutes of Health, Public Health Service, Department of Health and Human Services; 1997.\nWilson L, Brown JS, Shin GP, Luc KO, Subak LL: Annual direct cost of urinary incontinence. Obstet Gynecol 2001, 98: 398–406. 10.1016\u002FS0029-7844(01)01464-8\nAmerican Heart Association (AHA): Heart disease and stroke statistics - 2004 update [online]. [http:\u002F\u002Fwww.americanheart.org\u002Fdownloadable\u002Fheart\u002F1079736729696HDSStats2004UpdateREV3–19–04.pdf.]\nMovig KL, Leufkens HG, Lenderink AW, Egberts AC: Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 2003, 56: 530–535. 10.1016\u002FS0895-4356(03)00006-4\nNatkunam A, Shek CC, Swaminathan R: Hyponatremia in a hospital population. J Med 1991, 22: 83–96.\nMurphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, Marteau T: Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998, 2: i-iv, 1–88.\nCohen P, Cohen J: The clinician's illusion. Arch Gen Psychiatry 1984, 41: 1178–1182.\nSonnenblick M, Friedlander Y, Rosin AJ: Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993, 103: 601–606.\nFraser CL, Arieff AI: Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997, 102: 67–77. 10.1016\u002FS0002-9343(96)00274-4\nSchwartz WB, Bennett W, Curelop S, Bartter FC: A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957, 23: 529–542. 10.1016\u002F0002-9343(57)90224-3\nSchrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988, 319: 1065–1072.\nFlear CT, Gill GV, Burn J: Hyponatraemia: mechanisms and management. Lancet 1981, 2: 26–31. 10.1016\u002FS0140-6736(81)90261-0\nWestwater ML, Davies JC: Follow up of 742 tuberculosis patients. Follow up at eighteen months of 742 tuberculosis patients notified in midlands and south-eastern province in six months in 1964. Cent Afr J Med 1967, 13: 175–176.\nSamadi AR, Wahed MA, Islam MR, Ahmed SM: Consequences of hyponatraemia and hypernatraemia in children with acute diarrhoea in Bangladesh. Br Med J (Clin Res Ed) 1983, 286: 671–673.\nBennani SL, Abouqal R, Zeggwagh AA, Madani N, Abidi K, Zekraoui A, Kerkeb O: [Incidence, causes and prognostic factors of hyponatremia in intensive care]. Rev Med Interne 2003, 24: 224–229.\nNzerue CM, Baffoe-Bonnie H, You W, Falana B, Dai S: Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003, 95: 335–343.\nFrancis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82: 1724–1729.\nVerbalis JG: The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In Diseases of the Kidney. Edited by: Schrier RW. Philadelphia, Lippincott Williams and Wilkins; 2001:2511–2548.\nHirshberg B, Ben-Yehuda A: The syndrome of inappropriate antidiuretic hormone secretion in the elderly. Am J Med 1997, 103: 270–273. 10.1016\u002FS0002-9343(97)00250-7",{"EN":1471},"Hyponatremia is a disorder of fluid and electrolyte balance characterized by a relative excess of body water relative to body sodium content. It is the most common electrolyte disorder encountered in clinical medicine and is associated with negative outcomes in many chronic diseases. However, there is limited information in the literature about health care resource use and costs attributable to the effects of the condition. The purpose of this analysis was to estimate the annual cost of illness of hyponatremia in the United States. The study utilized a prevalence-based cost of illness framework that incorporated data from publicly available databases, published literature and a consensus panel of expert physicians. Panel members provided information on: classification of hyponatremia patients, treatment settings for hyponatremia (i.e., hospital, emergency room, doctor's office), and health care resource use associated with the diagnosis and treatment of hyponatremia. Low and high prevalence scenarios were estimated and utilized in a spreadsheet-based cost of illness model. Costs were assigned to units of resources and summarized across treatment settings. The prevalence estimate for hyponatremia ranged from 3.2 million to 6.1 million persons in the U.S. on an annual basis. Approximately 1% of patients were classified as having acute and symptomatic hyponatremia, 4% acute and asymptomatic, 15%–20% chronic and symptomatic, and 75–80% chronic and asymptomatic. Of patients treated for hyponatremia, 55%–63% are initially treated as inpatients, 25% are initially treated in the emergency room, and 13%–20% are treated solely in the office setting. The direct costs of treating hyponatremia in the U.S. on an annual basis were estimated to range between $1.6 billion and $3.6 billion. Treatment of hyponatremia represents a significant healthcare burden in the U.S. Newer therapies that may reduce the burden of hyponatremia in the inpatient setting could minimize the costs associated with this condition.",{"EN":1473},"Cost of illness of hyponatremia in the United States",{"VOID":1475},"10.1186\u002F1478-7547-4-10","https:\u002F\u002Fresource-allocation.biomedcentral.com\u002Farticles\u002F10.1186\u002F1478-7547-4-10",[1478,1493,1505],{"id":1479,"sortIndex":94,"researcher":18,"roles":1480,"affiliations":1481,"properties":1490},"c605307c-5eea-4b01-b035-e75c87ae89f1",[126],[1482],{"id":18,"sortIndex":19,"affiliation":1483,"properties":18},{"id":1484,"createTime":1485,"updateTime":1485,"relativeEntities":1486,"slug":18,"properties":1487,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b338a035-e613-41c6-91e4-9b4c1197c5a0","2024-01-27T18:15:40.432+00:00",[],{"title":1488},{"VI":1489},"United BioSource Corporation, Bethesda, USA",{"title":1491},{"VI":1492},"Clark Paramore",{"id":1494,"sortIndex":19,"researcher":18,"roles":1495,"affiliations":1496,"properties":1502},"ec498329-58c0-4fed-98a4-b350886f3415",[126],[1497],{"id":18,"sortIndex":19,"affiliation":1498,"properties":18},{"id":1484,"createTime":1485,"updateTime":1485,"relativeEntities":1499,"slug":18,"properties":1500,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1501},{"VI":1489},{"title":1503},{"VI":1504},"Audra Boscoe",{"id":1506,"sortIndex":257,"researcher":18,"roles":1507,"affiliations":1508,"properties":1519},"72bb3ed4-b9bc-45c6-ade5-ee4089daa5aa",[126],[1509],{"id":18,"sortIndex":19,"affiliation":1510,"properties":18},{"id":1511,"createTime":1512,"updateTime":1513,"relativeEntities":1514,"slug":1515,"properties":1516,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0c4f87c9-5357-49a7-a47d-33d862c141ca","2023-11-28T02:13:58.172+00:00","2025-06-12T01:08:15.404+00:00",[],"Georgetown-University-Medical-Center-Georgetown-University-Washington-USA",{"title":1517},{"VI":1518},"Georgetown University Medical Center, Georgetown University, Washington, USA",{"title":1520},{"VI":1521},"Joseph G Verbalis",{"url":1476,"publisher":1523,"properties":1550},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1524,"slug":10,"properties":1525,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1528,"manageAffiliations":1529,"indexDatabases":1530,"url":91,"thumbnailPath":18,"statistic":1545,"gsStatistic":18,"type":98,"analyzePriority":18},[],{"issn":1526,"title":1527},{"VOID":13},{"EN":15},[],[],[1531,1538],{"id":54,"indexDatabase":1532,"url":67,"indexYears":68,"academicFieldIds":1537,"indexDatabaseRanking":71},{"id":56,"createTime":57,"updateTime":58,"relativeEntities":1533,"label":1534,"description":1535,"key":64,"publicationTags":1536,"standard":18},[],{"EN":61,"VI":61},{"EN":61,"VI":63},[66],[70],{"id":73,"indexDatabase":1539,"url":88,"indexYears":18,"academicFieldIds":1544,"indexDatabaseRanking":18},{"id":75,"createTime":76,"updateTime":77,"relativeEntities":1540,"label":1541,"description":1542,"key":84,"publicationTags":1543,"standard":18},[],{"EN":80,"VI":80},{"VI":82,"EN":83},[86,87],[90],{"impactFactor":19,"impactFactorByYear":1546,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1547,"totalCitation":19,"totalCitationByYear":1548,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1549,"hindexLast5Year":19,"hindex":19},{},{"2021":94},{},{},{"volume":1551,"pages":1552},{"VOID":1146},{"VOID":1553},"1-11","2006-05-31"]